import { SubTopicPageData } from './subTopicData';

export const UK_SCIENCE_PAGES: SubTopicPageData[] = [
  {
    id: 'neuroscience',
    slug: 'uk-science-neuroscience',
    title: 'Neuroscience & Neurodegenerative Therapies',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'CNS Drug Discovery',
    executiveSummary: 'Advanced translational research targeting Alzheimer’s, Parkinson’s, and ALS through blood-brain barrier transport engineering and neuroinflammation targeting.',
    leadParagraph: 'Operating within the UK’s neuroscience research ecosystem, Bedfordshire Biotech develops novel biologic and small-molecule modalities capable of surmounting the blood-brain barrier to arrest neurodegenerative cascade mechanisms.',
    keyStats: [
      { label: 'Active CNS Assets', value: '4 Programs' },
      { label: 'BBB Penetrance', value: '14.2% Elevation' },
      { label: 'Research Consortium', value: 'UK Dementia Research' },
      { label: 'Synaptic Screening', value: '10,000 Nodes/Wk' }
    ],
    keyMethodologies: [
      {
        title: 'Receptor-Mediated Transcytosis Engineering',
        description: 'Bispecific antibody platforms utilizing transferrin receptor (TfR) shuttles to ferry therapeutic antibodies across the human blood-brain barrier.',
        tags: ['BBB Shuttle', 'TfR', 'Bispecific mAbs']
      },
      {
        title: 'Microglial Neuroinflammation Assays',
        description: 'Human iPSC-derived microglial cell screening evaluating suppression of neurotoxic cytokine release without impairing amyloid phagocytosis.',
        tags: ['Microglia', 'iPSC', 'Neuroinflammation']
      },
      {
        title: 'Quantitative CSF Biomarker Profiling',
        description: 'Single-molecule Simoa and mass spectrometry detection of neurofilament light chain (NfL) and phosphorylated tau-217 in cerebrospinal fluid.',
        tags: ['Biomarkers', 'NfL', 'Simoa']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Assay Sensitivity (NfL)', specification: '0.1 pg/mL via Quanterix Simoa HD-X', standard: 'UK Biobank Aligned' },
      { parameter: 'In Vitro BBB Transwell TEER', specification: '> 1,200 Ω·cm² microvascular resistance', standard: 'GLP Neurovascular Model' },
      { parameter: 'Receptor Affinity Window', specification: 'KD 50 nM to 250 nM for optimal transcytosis release', standard: 'Biophysical SPR Standard' },
      { parameter: 'Preclinical Brain/Serum Ratio', specification: '> 0.08 AUC brain to AUC plasma ratio', standard: 'ICH S6(R1) Preclinical Safety' }
    ],
    instrumentationAndPlatforms: [
      'Quanterix Simoa HD-X Analyzer',
      'Molecular Devices ImageXpress High Content Imager',
      'Cytiva Biacore 8K Surface Plasmon Resonance',
      'Cryogenic Tissue Micro-Dissection Cryostat'
    ],
    regulatoryCompliance: ['MHRA Clinical Trial Authorisation (CTA)', 'Human Tissue Authority (HTA) Licence', 'Good Laboratory Practice (GLP)'],
    clinicalSignificance: 'Translates laboratory insights into neuroprotective medicines capable of preserving cognitive function and slowing neuronal loss in degenerative brain diseases.',
    caseStudyOrApplication: {
      heading: 'Overcoming the Blood-Brain Barrier for Tau Silencing',
      synopsis: 'Designing a brain-shuttle bispecific antibody targeting pathological tau aggregates in preclinical Alzheimer’s models.',
      outcomes: [
        'Achieved 12-fold increase in brain parenchyma concentration compared to conventional IgG',
        'Demonstrated 68% reduction in toxic tau phosphorylation in cortical brain regions',
        'Progressed into MHRA Innovation Passport fast-track review'
      ]
    },
    contactFocus: 'Neuroscience Discovery Consortium & Licensing Enquiries'
  },
  {
    id: 'innovation-in-the-uk',
    slug: 'uk-science-innovation-in-the-uk',
    title: 'Innovation in the UK & Life Sciences Strategy',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'National Strategy',
    executiveSummary: 'Aligning with the UK Government Life Sciences Vision 2030, NHS England clinical research networks, and British breakthrough science clusters.',
    leadParagraph: 'Bedfordshire Biotech operates at the heart of the British life sciences sector, driving forward the UK’s strategic priorities in genomics, sovereign biomanufacturing, and rapid clinical translation in partnership with academic and NHS institutions.',
    keyStats: [
      { label: 'Strategic Alignment', value: 'Vision 2030' },
      { label: 'UK Capital Invested', value: '£85M+ Capex' },
      { label: 'Ecosystem Jobs', value: '420+ Skilled' },
      { label: 'Academic Partners', value: '16 Universities' }
    ],
    keyMethodologies: [
      {
        title: 'Golden Triangle Ecosystem Integration',
        description: 'Connecting Cambridge biological discoveries and Oxford spin-outs with our commercial cGMP manufacturing infrastructure in Greater London.',
        tags: ['Golden Triangle', 'Oxford', 'Cambridge']
      },
      {
        title: 'MHRA Regulatory Sandbox Pilots',
        description: 'Early engagement with the UK Medicines and Healthcare products Regulatory Agency under the Innovative Licensing and Access Pathway (ILAP).',
        tags: ['ILAP', 'MHRA', 'Regulatory Sandbox']
      },
      {
        title: 'Sovereign Biomanufacturing Resilience',
        description: 'Developing domestic supply chain capabilities to safeguard the UK against global shortages of critical vaccines and sterile injectables.',
        tags: ['Resilience', 'Biomanufacturing', 'Supply Chain']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Cleanroom Production Standards', specification: 'Full compliance with MHRA cGMP rules', standard: 'Orange Guide EU GMP' },
      { parameter: 'NHS Collaboration Protocols', specification: 'National Institute for Health and Care Research (NIHR) aligned', standard: 'NIHR Standard Model' },
      { parameter: 'Data Protection & Governance', specification: 'NHS DTAC and UK GDPR compliant', standard: 'ISO 27001 / Cyber Essentials Plus' },
      { parameter: 'Sustainability Targets', specification: 'Net-zero facility operations roadmap by 2030', standard: 'NHS Net Zero Supplier Roadmap' }
    ],
    instrumentationAndPlatforms: [
      'Industrial Enterprise ERP & LIMS Hub',
      'Advanced Bioprocessing Automation Suites',
      'Digital Twin Cleanroom Monitoring Sensors',
      'Telemetric Supply Chain Tracking Platform'
    ],
    regulatoryCompliance: ['UK Life Sciences Council Governance', 'Innovate UK Grant Compliance', 'Department for Science, Innovation and Technology (DSIT) Aligned'],
    clinicalSignificance: 'Ensures that British patients gain priority access to domestic medical innovations while cementing the UK as a premier global destination for life sciences investment.',
    caseStudyOrApplication: {
      heading: 'Accelerated NHS Clinical Rollout via ILAP Framework',
      synopsis: 'Deploying a targeted oncology biologic through the MHRA Innovative Licensing and Access Pathway in collaboration with 5 NHS Trusts.',
      outcomes: [
        'Secured Innovation Passport status within 6 weeks of initial submission',
        'Reduced Phase II approval timeline by 4 months via parallel MHRA and NICE scientific advice',
        'First patient recruited 60 days post-authorisation across UK clinical trial sites'
      ]
    },
    contactFocus: 'UK Strategic Partnerships & Government Liaison'
  },
  {
    id: 'drug-delivery-and-biomaterials',
    slug: 'uk-science-drug-delivery-and-biomaterials',
    title: 'Drug Delivery and Biomaterials (UK Innovations)',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'Advanced Delivery Systems',
    executiveSummary: 'Next-generation lipid nanoparticle architectures, polymer depot matrices, and inhaled dry powders engineered within our UK research laboratories.',
    leadParagraph: 'Overcoming complex drug administration challenges through advanced British engineering. Our biomaterials team designs bespoke delivery systems for genetic medicines, peptides, and fragile biotherapeutics.',
    keyStats: [
      { label: 'Formulation Library', value: '350+ Variants' },
      { label: 'Bioavailability Boost', value: '4.6x Higher' },
      { label: 'Thermal Stability', value: 'Up to 25°C / 6 Mos' },
      { label: 'UK Patents Granted', value: '18 Patents' }
    ],
    keyMethodologies: [
      {
        title: 'Microfluidic Continuous Formulation',
        description: 'High-shear micromixing producing uniform nanocarriers with tightly controlled size distributions and encapsulation efficiencies exceeding 95%.',
        tags: ['Microfluidics', 'Nanocarriers', 'LNP']
      },
      {
        title: 'Biodegradable In Situ Gel Depots',
        description: 'Polylactide-co-glycolide copolymer platforms providing sustained zero-order subcutaneous release over periods ranging from 1 to 6 months.',
        tags: ['Depots', 'PLGA', 'Sustained Release']
      },
      {
        title: 'Engineered Inhaled Aerosol Particles',
        description: 'Spray-dried porous microparticles optimized for deep lung deposition and systemic absorption of peptide therapeutics.',
        tags: ['Inhalation', 'Spray Drying', 'Pulmonary Delivery']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Nanoparticle Size Uniformity', specification: 'Polydispersity Index (PDI) < 0.08', standard: 'ISO 22412 DLS Standards' },
      { parameter: 'Payload Encapsulation Rate', specification: '> 95% intact biopolymer encapsulation', standard: 'HPLC / Ribogreen Assay' },
      { parameter: 'Degradation By-Products', specification: 'Non-toxic, fully metabolizable biological metabolites', standard: 'ISO 10993 Biocompatibility' },
      { parameter: 'Sterility Assurance Level (SAL)', specification: '10⁻⁶ via terminal filtration or aseptic process', standard: 'Ph. Eur. 5.1.1' }
    ],
    instrumentationAndPlatforms: [
      'Precision NanoSystems Blaze Automated Formulator',
      'Büchi B-290 Mini Spray Dryer with Inert Loop',
      'Next Generation Impactor (NGI) for Aerosols',
      'Malvern Panalytical Zetasizer Ultra'
    ],
    regulatoryCompliance: ['MHRA Good Manufacturing Practice', 'ISO 10993 Biological Evaluation of Medical Devices', 'USP <1151> Dosage Forms'],
    clinicalSignificance: 'Converts challenging chemical and genetic compounds into stable, patient-friendly therapies that can be administered in clinic or at home.',
    caseStudyOrApplication: {
      heading: 'Room-Temperature Stable mRNA LNP Vaccine Delivery',
      synopsis: 'Developing a novel ionizable lipid composition that preserves mRNA integrity without requiring ultra-cold sub-zero storage.',
      outcomes: [
        'Maintained >90% transfection efficiency after 6 months at 2–8°C refrigerated conditions',
        'Achieved full humoral immune response in preclinical challenge models',
        'Patented formulation licensed to UK commercial development partners'
      ]
    },
    contactFocus: 'Drug Delivery Platform Licensing & Formulation Services'
  },
  {
    id: 'clinical-trials',
    slug: 'uk-science-clinical-trials',
    title: 'Clinical Trials & Investigative Studies in the UK',
    category: 'UK Science',
    subCategory: 'Clinical Development',
    heroBadge: 'Phase I–III Clinical Operations',
    executiveSummary: 'Designing, managing, and supplying Phase I through Phase III clinical trials across UK hospital sites and the NIHR experimental medicine infrastructure.',
    leadParagraph: 'Navigating the British clinical trial ecosystem with regulatory rigor. We provide clinical supply manufacturing, trial management, bioanalytical sample monitoring, and QP release for experimental therapeutics.',
    keyStats: [
      { label: 'Active Trial Sites', value: '48 UK Hospitals' },
      { label: 'Patients Enrolled', value: '3,200+ Subjects' },
      { label: 'CTA Approval Rate', value: '100% First Submission' },
      { label: 'QP Batch Release', value: '< 5 Days' }
    ],
    keyMethodologies: [
      {
        title: 'Adaptive Clinical Trial Architecture',
        description: 'Seamless Phase I/II trial designs utilizing Bayesian statistical frameworks to optimize dosing cohorts and accelerate efficacy signals.',
        tags: ['Adaptive Trials', 'Bayesian', 'Phase I/II']
      },
      {
        title: 'Investigational Medicinal Product (IMP) Supply',
        description: 'Complete cGMP manufacturing, primary and secondary packaging, cold-chain distribution, and Qualified Person (QP) release under MIA(IMP).',
        tags: ['IMP', 'QP Release', 'Clinical Supply']
      },
      {
        title: 'Decentralized & Hybrid Patient Monitoring',
        description: 'Remote biomarker collection, digital patient diaries, and home healthcare nursing protocols to maximize trial retention.',
        tags: ['Decentralized', 'Patient Retention', 'Digital Health']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Regulatory Ethics Protocol', specification: 'IRAS combined review and MHRA CTA clearance', standard: 'UK Clinical Trials Regulations' },
      { parameter: 'Qualified Person (QP) Certification', specification: 'MIA(IMP) release according to Annex 13/16', standard: 'MHRA MIA(IMP) Licence' },
      { parameter: 'Clinical Data Integrity', specification: 'CDISC compliant electronic data capture (EDC)', standard: 'ICH E6(R2) Good Clinical Practice' },
      { parameter: 'Temperature Deviations Permitted', specification: 'Zero critical excursions in trial medication transit', standard: 'GDP Clinical Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Medidata Rave eCRF & EDC Data Architecture',
      'Validated Clinical Packaging & Randomization Suite',
      'Automated Temperature-Controlled Secondary Labeling Line',
      '24/7 Clinical Supply Depot & Cold-Chain Vault'
    ],
    regulatoryCompliance: ['Medicines for Human Use (Clinical Trials) Regulations 2004', 'ICH E6(R2) Good Clinical Practice (GCP)', 'MHRA MIA(IMP) Manufacturer Authorisation', 'NHS Research Ethics Committee (REC)'],
    clinicalSignificance: 'Ensures clinical trials progress with speed, patient safety, and regulatory compliance, generating robust data acceptable to the MHRA, EMA, and FDA.',
    caseStudyOrApplication: {
      heading: 'Rapid Setup of Multi-Center UK Phase II Oncology Trial',
      synopsis: 'Deploying an investigational bispecific antibody across 14 NHS experimental cancer medicine centres under tight deadlines.',
      outcomes: [
        'Secured joint MHRA CTA and REC ethical approval within 42 calendar days',
        'Manufactured and QP-released 1,200 patient kits with custom cryogenic packaging',
        'Recruited 100% of trial cohort 3 months ahead of national recruitment target'
      ]
    },
    contactFocus: 'Clinical Supply Services & Trial Management Contracts'
  },
  {
    id: 'technologies-platforms',
    slug: 'uk-science-technologies-platforms',
    title: 'Technologies & Discovery Platforms',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'Discovery Platforms',
    executiveSummary: 'Next-generation multi-omics, high-content phenotypic screening, single-cell genomics, and robotic bio-foundry automation engines.',
    leadParagraph: 'Harnessing advanced discovery instrumentation to unlock novel therapeutic mechanisms. Our technology platforms combine laboratory automation, spatial imaging, and machine learning to accelerate lead generation.',
    keyStats: [
      { label: 'Automated Runs/Mo', value: '450 Screening Runs' },
      { label: 'Genomic Depths', value: '100x Coverage' },
      { label: 'Hit-to-Lead Time', value: '< 9 Months' },
      { label: 'Bioinformatics Cores', value: '500+ CPU Nodes' }
    ],
    keyMethodologies: [
      {
        title: 'Spatial Transcriptomics & In Situ Profiling',
        description: 'Mapping gene expression at single-cell resolution directly within intact histological tissue sections to understand disease architecture.',
        tags: ['Spatial Omics', 'Single-Cell', 'In Situ']
      },
      {
        title: 'Robotic Screening Biofoundry',
        description: 'Automated liquid handling and plate imaging pipelines executing compound screening, cell maintenance, and assay readouts with minimal hands-on time.',
        tags: ['Robotics', 'Biofoundry', 'High-Throughput']
      },
      {
        title: 'Proteome-Wide Target Profiling',
        description: 'Thermal proteome profiling and chemical proteomics identifying direct intracellular protein binders in living cellular systems.',
        tags: ['Proteomics', 'Target ID', 'Chemical Biology']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Assay Plate Density', specification: '96-well, 384-well, and 1536-well microplates', standard: 'SLAS Microplate Standards' },
      { parameter: 'Imaging Optical Resolution', specification: '0.22 µm confocal fluorescence resolution', standard: 'ISO 19012 Optics' },
      { parameter: 'Pipetting Accuracy', specification: '< 2.0% CV down to 50 nL acoustic dispensing', standard: 'ISO 8655 Liquid Handling' },
      { parameter: 'Cloud Compute Infrastructure', specification: 'Automated Nextflow bioinformatic pipelines', standard: 'GA4GH Genomic Standards' }
    ],
    instrumentationAndPlatforms: [
      'Echo 650 Acoustic Liquid Handler',
      'PerkinElmer Opera Phenix Plus High-Content Screener',
      '10x Genomics Chromium X Single-Cell Controller',
      'High-Performance Hybrid Cloud Compute Cluster'
    ],
    regulatoryCompliance: ['ISO 9001:2015 Quality Management', 'GLP Standards for Discovery Testing', 'FAIR Data Principles Compliant'],
    clinicalSignificance: 'Drives the discovery of higher-affinity, lower-toxicity drug candidates by screening vast biological spaces with speed and fidelity.',
    caseStudyOrApplication: {
      heading: 'Uncovering Novel Immune Checkpoint via Spatial Screening',
      synopsis: 'Deploying spatial transcriptomics across 80 refractory tumor sections to pinpoint localized immunosuppressive drivers.',
      outcomes: [
        'Identified a previously uncharacterized micro-niche signaling loop suppressing T-cell activation',
        'Developed functional blocking antibodies against the discovered target within 16 weeks',
        'Initiated intellectual property filing and preclinical development program'
      ]
    },
    contactFocus: 'Platform Access & Collaborative Screening Programs'
  },
  {
    id: 'material-characterisation-team',
    slug: 'uk-science-material-characterisation-team',
    title: 'Material Characterisation Team',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Physical Chemistry & Solid State',
    executiveSummary: 'Solid-state polymorph screening, particle sizing, thermal analysis, dynamic vapor sorption, and powder rheology for pharmaceutical materials.',
    leadParagraph: 'Ensuring consistent physical and chemical behavior in drug substances and excipients. Our material characterisation team investigates crystal structures, powder flowability, and solid-state stability under varied environmental conditions.',
    keyStats: [
      { label: 'Polymorph Screens', value: '180+ Completed' },
      { label: 'Thermal Precision', value: '± 0.01°C DSC' },
      { label: 'Powder Flow Indices', value: 'Carr & Hausner' },
      { label: 'Turnaround Time', value: '3–5 Days' }
    ],
    keyMethodologies: [
      {
        title: 'Solid-State Polymorph & Salt Screening',
        description: 'Systematic crystallization experiments evaluating solvates, hydrates, and polymorphic forms to select the most stable solid form for development.',
        tags: ['Polymorphs', 'Crystallization', 'Solid-State']
      },
      {
        title: 'Thermal Analysis (DSC & TGA)',
        description: 'Differential scanning calorimetry and thermogravimetric analysis quantifying melting endotherms, glass transitions, and solvent desolvation steps.',
        tags: ['DSC', 'TGA', 'Thermal Properties']
      },
      {
        title: 'Dynamic Vapor Sorption (DVS)',
        description: 'Gravimetric moisture uptake measurement determining hygroscopicity, deliquescence points, and moisture-induced amorphous-crystalline transitions.',
        tags: ['DVS', 'Hygroscopicity', 'Moisture Sorption']
      }
    ],
    technicalSpecifications: [
      { parameter: 'X-Ray Powder Diffraction (XRPD)', specification: 'Cu K-alpha radiation, Bragg-Brentano geometry', standard: 'Ph. Eur. 2.9.33 / USP <941>' },
      { parameter: 'Laser Diffraction Particle Sizing', specification: 'Dynamic range from 10 nm to 3,500 µm', standard: 'ISO 13320 / USP <429>' },
      { parameter: 'Specific Surface Area (BET)', specification: 'Multipoint nitrogen gas adsorption', standard: 'ISO 9277 / USP <846>' },
      { parameter: 'Powder Rheology & Compressibility', specification: 'FT4 Powder Rheometer flow energy testing', standard: 'ASTM D7891 Standards' }
    ],
    instrumentationAndPlatforms: [
      'Malvern Panalytical Aeris Benchtop XRD',
      'TA Instruments Discovery DSC 2500 & TGA 5500',
      'Surface Measurement Systems DVS Resolution',
      'Freeman Technology FT4 Powder Rheometer'
    ],
    regulatoryCompliance: ['ICH Q6A Specifications for New Drug Substances', 'USP <941> Characterization of Crystalline and Partially Crystalline Solids', 'GLP / cGMP Laboratory Standards'],
    clinicalSignificance: 'Prevents catastrophic changes in drug bioavailability, tablet hardness, or chemical stability caused by unexpected polymorph conversions during manufacturing or storage.',
    caseStudyOrApplication: {
      heading: 'Identifying Metastable Polymorph in Tableting Scale-Up',
      synopsis: 'A client encountered tablet capping and dissolution failures when transitioning an oral API to commercial high-speed tableting.',
      outcomes: [
        'XRPD and DSC analysis pinpointed an undocumented Form III polymorph induced by compression shear stress',
        'Reformulated crystallization parameters to lock API into thermodynamically stable Form I',
        'Restored consistent dissolution rates and eliminated tablet defects across 5 validation batches'
      ]
    },
    contactFocus: 'Solid-State Chemistry & Powder Characterisation Inquiries'
  },
  {
    id: 'virology',
    slug: 'uk-science-virology',
    title: 'Virology & Antiviral Therapeutics',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'BSL-3 Virology Laboratory',
    executiveSummary: 'High-containment virology testing, viral vector characterization, antiviral screening, and neutralizing antibody assays against emerging pathogens.',
    leadParagraph: 'Operating dedicated Biosafety Level 2 and Level 3 containment facilities, our virology teams assess antiviral drugs, evaluate therapeutic neutralizing antibodies, and characterize viral delivery vectors for gene therapies.',
    keyStats: [
      { label: 'Containment Level', value: 'BSL-2 & BSL-3' },
      { label: 'Viral Strains', value: '28 Maintained' },
      { label: 'Assay Throughput', value: '2,500 Wells/Wk' },
      { label: 'Plaque Assay Accuracy', value: 'CV < 8%' }
    ],
    keyMethodologies: [
      {
        title: 'Pseudovirus Neutralization Assays (PVNA)',
        description: 'High-throughput reporter pseudovirus platforms evaluating serum antibody neutralization titers against mutant viral spike and surface proteins.',
        tags: ['Neutralization', 'Pseudovirus', 'Antibodies']
      },
      {
        title: 'Live Virus Plaque Reduction Testing (PRNT)',
        description: 'Gold-standard quantitative plaque assays in BSL-3 facilities measuring true infectious virus reduction following antiviral treatment.',
        tags: ['Live Virus', 'BSL-3', 'PRNT']
      },
      {
        title: 'AAV & Lentiviral Vector Titering',
        description: 'Droplet digital PCR and analytical ultracentrifugation measuring full vs empty capsid ratios and functional viral genomes.',
        tags: ['AAV', 'Gene Therapy', 'Vector Titers']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Containment Certification', specification: 'Advisory Committee on Dangerous Pathogens (ACDP) Level 3', standard: 'UK HSE Containment Rules' },
      { parameter: 'Detection Sensitivity', specification: 'Single plaque-forming unit (PFU) per well', standard: 'WHO Virology Guidelines' },
      { parameter: 'Air Handling & Filtration', specification: 'Negative pressure cascade with dual HEPA exhaust', standard: 'BSL-3 Engineering Controls' },
      { parameter: 'Vector Titering Standard', specification: 'Absolute genome copies/mL via ddPCR', standard: 'Ph. Eur. 5.14 Gene Therapy' }
    ],
    instrumentationAndPlatforms: [
      'Biosafety Level 3 Walk-In Microbiological Suite',
      'Bio-Tek Cytation 5 Cell Imaging Multi-Mode Reader',
      'Beckman Coulter Optima AUC Analytical Ultracentrifuge',
      'Bio-Rad QX200 Droplet Digital PCR System'
    ],
    regulatoryCompliance: ['UK Health and Safety Executive (HSE) BSL-3 Approval', 'Department for Environment, Food and Rural Affairs (DEFRA) Licences', 'GLP Compliant Virology Suites'],
    clinicalSignificance: 'Delivers essential non-clinical efficacy and safety evidence required to advance antiviral drugs and gene therapy vectors into clinical trials.',
    caseStudyOrApplication: {
      heading: 'Rapid Neutralization Screening Against Novel Viral Variant',
      synopsis: 'Evaluating neutralizing potency of a panel of monoclonal antibodies against an emerging respiratory viral variant of concern.',
      outcomes: [
        'Engineered pseudovirus reporter system within 10 days of published genetic sequence',
        'Screened 45 antibody candidates, identifying 3 retaining picomolar neutralizing activity',
        'Provided essential preclinical dossier supporting emergency CTA authorization'
      ]
    },
    contactFocus: 'Virology Testing & Viral Vector Characterisation Contracts'
  },
  {
    id: 'pharmaceutical-sciences',
    slug: 'uk-science-pharmaceutical-sciences',
    title: 'Pharmaceutical Sciences & Drug Product Development',
    category: 'UK Science',
    subCategory: 'Formulation & Manufacturing',
    heroBadge: 'Pharmaceutical Development',
    executiveSummary: 'Integrated preformulation, solubility enhancement, dosage form prototyping, and scale-up engineering for oral, parenteral, and topical pharmaceuticals.',
    leadParagraph: 'Bridging chemical discovery and commercial manufacturing. Our pharmaceutical scientists develop robust dosage forms that maximize bioavailability, ensure physical stability, and scale seamlessly into cGMP production.',
    keyStats: [
      { label: 'Molecules Developed', value: '220+ APIs' },
      { label: 'Bioavailability Gains', value: 'Up to 8x' },
      { label: 'Pilot Scale Batch', value: 'Up to 50 kg' },
      { label: 'Formulation Success', value: '98.5%' }
    ],
    keyMethodologies: [
      {
        title: 'Lipid-Based Drug Delivery (SEDDS/SMEDDS)',
        description: 'Self-emulsifying isotropic lipid formulations converting poorly water-soluble BCS Class II/IV compounds into bioavailable oral solutions.',
        tags: ['SEDDS', 'Lipid Delivery', 'Bioavailability']
      },
      {
        title: 'Hot Melt Extrusion (HME) Amorphous Dispersions',
        description: 'Twin-screw extrusion dispersing active molecules in polymeric matrices to stabilize high-energy amorphous forms and prevent recrystallization.',
        tags: ['HME', 'Amorphous', 'Twin-Screw']
      },
      {
        title: 'Aseptic Parenteral Lyophilization Design',
        description: 'Formulation and cycle design for sterile injectable vials, maintaining active protein folding and cake stability over multi-year shelf-life.',
        tags: ['Lyophilization', 'Injectables', 'Parenteral']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Dissolution Testing Apparatus', specification: 'USP Apparatus 1 (Basket), 2 (Paddle), 4 (Flow-Through)', standard: 'USP <711> / Ph. Eur. 2.9.3' },
      { parameter: 'Extrusion Processing Temperature', specification: 'Precise barrel control up to 300°C', standard: 'cGMP Extrusion Standards' },
      { parameter: 'Injectable Particle Limits', specification: '< 6,000 particles ≥ 10 µm / container', standard: 'USP <788> Sterile Injections' },
      { parameter: 'Stability Protocol Compliance', specification: 'Full ICH zone conditions (I through IVb)', standard: 'ICH Q1A(R2)' }
    ],
    instrumentationAndPlatforms: [
      'Sotax AT 70 Smart Dissolution Testing Station',
      'Thermo Scientific Pharma 11 Twin-Screw Extruder',
      'SP Scientific VirTis Genesis Pilot Lyophilizer',
      'Fette Compacting Single-Station Tablet Press'
    ],
    regulatoryCompliance: ['MHRA cGMP Manufacturer Licence', 'ICH Q8 Pharmaceutical Development Guidelines', 'FDA 21 CFR Part 211', 'Ph. Eur. Dosage Form Monographs'],
    clinicalSignificance: 'Ensures medicine safety, efficacy, and ease of patient compliance through scientifically optimized pharmaceutical delivery vehicles.',
    caseStudyOrApplication: {
      heading: 'Solubility Enhancement of Insoluble Kinase Inhibitor',
      synopsis: 'A BCS Class II oncology molecule showed low and erratic oral absorption in early preclinical trials.',
      outcomes: [
        'Formulated a spray-dried amorphous solid dispersion using HPMC-AS polymer',
        'Achieved an 8.4-fold increase in rat plasma AUC and reduced pharmacokinetic variability by 60%',
        'Successfully manufactured 20 kg of clinical trial tablets for UK Phase I trials'
      ]
    },
    contactFocus: 'Drug Product Development & Solubility Formulation Services'
  },
  {
    id: 'material-science',
    slug: 'uk-science-material-science',
    title: 'Material Science & Advanced Polymers',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Polymer & Material Physics',
    executiveSummary: 'Characterization of pharmaceutical polymers, medical device materials, packaging barrier films, and bio-erodible surgical matrices.',
    leadParagraph: 'Investigating the mechanical, structural, and chemical properties of materials used across healthcare. We evaluate biocompatibility, polymer degradation kinetics, and barrier performance for container closure systems.',
    keyStats: [
      { label: 'Materials Tested', value: '400+ Polymers' },
      { label: 'Mechanical Testing', value: 'Tensile & Shear' },
      { label: 'Barrier Permeation', value: 'WVTR & OTR' },
      { label: 'Extractables Testing', value: 'ISO 10993' }
    ],
    keyMethodologies: [
      {
        title: 'Gel Permeation Chromatography (GPC/SEC)',
        description: 'Multi-detector size-exclusion chromatography measuring absolute molecular weight distributions (Mw, Mn, PDI) of polymers.',
        tags: ['GPC', 'SEC', 'Molecular Weight']
      },
      {
        title: 'Water Vapor & Oxygen Transmission Testing',
        description: 'MOCON instrumentation measuring permeation rates through blister foils, polymer vials, and primary closure systems.',
        tags: ['Barrier Films', 'Permeation', 'WVTR']
      },
      {
        title: 'Dynamic Mechanical Analysis (DMA)',
        description: 'Characterizing viscoelastic modulus, damping factors, and mechanical glass transition temperatures under dynamic stress.',
        tags: ['DMA', 'Viscoelasticity', 'Mechanical Testing']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Molecular Weight Range', specification: '500 Da to 5,000,000 Da via triple-detection GPC', standard: 'ASTM D5296 / ISO 13885' },
      { parameter: 'WVTR Detection Limit', specification: '0.005 g/(m²·day) moisture transmission', standard: 'ASTM F1249 / ISO 15106' },
      { parameter: 'Mechanical Load Cell', specification: '0.5 N to 50 kN precision tensile frames', standard: 'ISO 527 Plastic Testing' },
      { parameter: 'Extractables Profiling', specification: 'HS-GC-MS, LC-HRMS, and ICP-MS screening', standard: 'PQRI Extractables Guide' }
    ],
    instrumentationAndPlatforms: [
      'Malvern Panalytical OMNISEC Triple Detection GPC',
      'MOCON PERMATRAN-W & OX-TRAN Permeation Analyzers',
      'TA Instruments Discovery DMA 850 Dynamic Mechanical Analyzer',
      'Instron 5966 Dual Column Universal Testing Frame'
    ],
    regulatoryCompliance: ['ISO 10993 Biological Evaluation of Medical Devices', 'USP <661> Plastic Packaging Systems', 'Ph. Eur. 3.1 Materials Used for Container Manufacture'],
    clinicalSignificance: 'Ensures container closures maintain drug sterility and prevents leaching of toxic monomers into sensitive injectable medications.',
    caseStudyOrApplication: {
      heading: 'Container Closure Integrity for Deep Cryogenic Storage',
      synopsis: 'Evaluating polymer vial elastomer seals for brittle failure and leakages at ultra-low temperatures (-150°C).',
      outcomes: [
        'DMA testing revealed critical elastomer glass transition threshold at -125°C',
        'Identified customized fluoropolymer blend retaining elastomeric seal compliance down to -160°C',
        'Demonstrated zero helium leak ingress over 3 months of cryogenic storage'
      ]
    },
    contactFocus: 'Polymer Testing & Packaging Material Evaluation Contracts'
  },
  {
    id: 'developing-new-medicines',
    slug: 'uk-science-developing-new-medicines',
    title: 'Developing New Medicines: From Target to Clinic',
    category: 'UK Science',
    subCategory: 'Clinical Development',
    heroBadge: 'End-to-End Drug Translation',
    executiveSummary: 'Full-spectrum medicine translation covering target validation, lead optimization, IND-enabling safety packages, and clinical phase execution.',
    leadParagraph: 'Guiding breakthrough molecules from benchtop concepts into approved clinical therapies. Bedfordshire Biotech deploys integrated teams across chemistry, biology, DMPK, and regulatory affairs to advance therapeutic pipelines efficiently.',
    keyStats: [
      { label: 'Pipeline Candidates', value: '18 Active' },
      { label: 'IND/CTA Filings', value: '12 Cleared' },
      { label: 'First-in-Human Rate', value: '100% On Time' },
      { label: 'Patent Estate', value: '45 Families' }
    ],
    keyMethodologies: [
      {
        title: 'Integrated IND-Enabling Package Delivery',
        description: 'Harmonized execution of GLP toxicology, safety pharmacology, bioanalysis, and cGMP drug substance manufacture under a unified timeline.',
        tags: ['IND-Enabling', 'GLP Tox', 'Safety Packages']
      },
      {
        title: 'Translational PK/PD Human Dose Forecasting',
        description: 'Allometric scaling and physiologically based pharmacokinetic (PBPK) simulations calculating safe human starting doses and efficacy targets.',
        tags: ['PBPK', 'Dose Prediction', 'PK/PD']
      },
      {
        title: 'Regulatory Scientific Advice Strategies',
        description: 'Constructive early engagement with the MHRA, EMA, and FDA to validate clinical trial endpoints and non-clinical packages.',
        tags: ['Regulatory Advice', 'MHRA', 'FDA Briefing']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Safety Pharmacology Battery', specification: 'Core battery: CNS, cardiovascular (hERG/telemetry), respiratory', standard: 'ICH S7A & S7B Guidelines' },
      { parameter: 'Genetic Toxicology Screening', specification: 'Ames test, in vitro micronucleus, in vivo comet assay', standard: 'ICH S2(R1) Testing' },
      { parameter: 'Repeat-Dose Toxicology Duration', specification: '28-day rodent and non-rodent GLP studies', standard: 'ICH M3(R2) Nonclinical Safety' },
      { parameter: 'Clinical Trial Authorisation (CTA)', specification: 'Complete Investigational Medicinal Product Dossier (IMPD)', standard: 'MHRA CTA Guidance' }
    ],
    instrumentationAndPlatforms: [
      'Fully Integrated Discovery & Analytical Labs',
      'Certara Phoenix WinNonlin & Simcyp PBPK Software',
      'Electronic Regulatory Dossier Publishing Suite',
      'cGMP Clinical Batch Manufacturing Cleanrooms'
    ],
    regulatoryCompliance: ['ICH Safety Guidelines (S Series)', 'MHRA Good Clinical Practice (GCP)', 'OECD Principles of Good Laboratory Practice (GLP)', 'ICH M3(R2) Guidance'],
    clinicalSignificance: 'Ensures that every new medicine entering clinical trials possesses verified mechanistic rationale, established safety margins, and high pharmaceutical quality.',
    caseStudyOrApplication: {
      heading: 'Accelerated Transition from Hit to Clinical Phase I in 18 Months',
      synopsis: 'A novel immune-oncology enzyme inhibitor program requiring fast-track progression to first-in-human clinical trials.',
      outcomes: [
        'Executed lead optimization, PK/PD modeling, and 28-day GLP toxicology concurrently',
        'Manufactured 5 kg of cGMP drug substance with >99.4% chemical purity',
        'Received MHRA CTA approval without grounds for non-acceptance on first submission'
      ]
    },
    contactFocus: 'Translational Medicine Development & Drug Discovery Partnerships'
  },
  {
    id: 'custom-synthesis-and-fine-chemical',
    slug: 'uk-science-custom-synthesis-and-fine-chemical',
    title: 'Custom Synthesis and Fine Chemical Manufacturing',
    category: 'UK Science',
    subCategory: 'Chemistry',
    heroBadge: 'Custom Organic Synthesis',
    executiveSummary: 'Bespoke synthesis of complex organic molecules, reference standards, stable isotope-labeled compounds, and high-potency intermediates from milligram to multi-kilogram scale.',
    leadParagraph: 'Solving difficult synthetic challenges for research institutes and pharmaceutical developers. Our synthetic chemists handle air-sensitive reagents, complex multi-step organic pathways, and stereoselective chemistry with precision.',
    keyStats: [
      { label: 'Synthetic Steps', value: 'Up to 24 Steps' },
      { label: 'Batch Range', value: '1 mg to 25 kg' },
      { label: 'Synthesis Success', value: '96.8%' },
      { label: 'NMR & HRMS COA', value: '100% Characterized' }
    ],
    keyMethodologies: [
      {
        title: 'Multi-Step Complex Organic Synthesis',
        description: 'Executing challenging retrosynthetic routes including macrocyclizations, carbohydrate chemistry, and sterically hindered coupling reactions.',
        tags: ['Custom Synthesis', 'Retrosynthesis', 'Multi-Step']
      },
      {
        title: 'Stable Isotope Labeling (¹³C, ²H, ¹⁵N)',
        description: 'Incorporating stable isotopic tags into drug molecules and endogenous metabolites for quantitative LC-MS internal standards.',
        tags: ['Stable Isotopes', 'Deuteration', 'Internal Standards']
      },
      {
        title: 'High-Potency Active Compound Handling',
        description: 'Contained synthesis suites equipped with barrier isolators engineered for compounds with Occupational Exposure Limits (OEL) < 0.1 µg/m³.',
        tags: ['HPAPI', 'Containment', 'Cytotoxics']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Analytical Purity (HPLC/GC)', specification: '≥ 98.0% standard, up to 99.9% on request', standard: 'ISO 9001 Certificate of Analysis' },
      { parameter: 'Isotopic Enrichment', specification: '≥ 99 atom % D or ¹³C incorporation', standard: 'High-Resolution Mass Spec' },
      { parameter: 'Reactor Working Volumes', specification: '100 mL round-bottom flasks to 100L jacketed glass reactors', standard: 'Glassware ASTM E438' },
      { parameter: 'Containment Classification', specification: 'Safebridge OEB 4 / OEB 5 certified isolators', standard: 'ISPE Containment Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Buchiglas 50L & 100L Pilot Scale Jacketed Glass Reactors',
      'Biotage Isolera Automated Flash Purification Systems',
      'Bruker 600 MHz NMR Spectrometer with CryoProbe',
      'Walk-In Laminar Downflow Containment Booths'
    ],
    regulatoryCompliance: ['ISO 9001:2015 Quality Management System', 'COSHH Safe Handling Regulations', 'Chemical Weapons Convention (CWC) Compliance', 'REACH Registered'],
    clinicalSignificance: 'Supplies high-purity reference materials, metabolites, and synthetic intermediates essential for accurate bioanalysis and early preclinical proof-of-concept.',
    caseStudyOrApplication: {
      heading: 'Synthesis of Hexa-Deuterated Internal Standard for Clinical Trial',
      synopsis: 'A clinical sponsor required 50 g of a d6-deuterated clinical candidate for an upcoming pharmacokinetic trial with tight deadlines.',
      outcomes: [
        'Devised a 7-step enantioselective route incorporating deuterated building blocks at penultimate stage',
        'Achieved 99.6% chemical purity and >99.2% isotopic enrichment confirmed by HRMS and NMR',
        'Delivered complete certificate of analysis and material within 6 weeks of contract signing'
      ]
    },
    contactFocus: 'Custom Synthesis Quotes & High-Potency Chemistry Inquiries'
  },
  {
    id: 'product-deformulation',
    slug: 'uk-science-product-deformulation',
    title: 'Product Deformulation & Reverse Engineering',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Chemical Reverse Engineering',
    executiveSummary: 'Deformulation, excipient quantitation, competitive benchmarking, and patent infringement analysis for complex pharmaceutical and cosmetic formulations.',
    leadParagraph: 'Dissecting complex formulated products to identify qualitative and quantitative compositions (Q1/Q2 sameness). We combine advanced chromatographic separations with spectroscopic isolation to identify excipient and API matrices.',
    keyStats: [
      { label: 'Deformulations Done', value: '140+ Products' },
      { label: 'Excipient Identification', value: '99.5% Accuracy' },
      { label: 'Q1/Q2 Sameness', value: 'FDA/MHRA Validated' },
      { label: 'Average Project Time', value: '3–6 Weeks' }
    ],
    keyMethodologies: [
      {
        title: 'Selective Matrix Extraction & Fractionation',
        description: 'Orthogonal solvent partitioning, solid-phase extraction, and preparative chromatography separating volatile, soluble, and insoluble matrix fractions.',
        tags: ['Extraction', 'Fractionation', 'Sample Prep']
      },
      {
        title: 'Spectroscopic & Microscopic Excipient Identification',
        description: 'Micro-FTIR, NMR, and Raman mapping identifying polymer binders, disintegrants, lubricants, and surfactants within tablet cores.',
        tags: ['Excipients', 'FTIR', 'Spectroscopy']
      },
      {
        title: 'Quantitative Chromatographic Profiling',
        description: 'Coupled GC-MS, LC-MS/MS, and ion chromatography quantifying exact percentages of active ingredients, preservatives, and solubilizers.',
        tags: ['Quantitation', 'GC-MS', 'Q1/Q2 Sameness']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Quantitative Precision', specification: 'Within ± 2% of actual formulation composition', standard: 'FDA Draft Guidance on Q1/Q2 Sameness' },
      { parameter: 'Polymer Molecular Weight Analysis', specification: 'GPC/SEC comparison against reference excipient grades', standard: 'Ph. Eur. Excipient Monographs' },
      { parameter: 'Surfactant & Preservative LOD', specification: '< 0.01% w/w in complex matrices', standard: 'ICH Q2(R1) Validated Methods' },
      { parameter: 'Patent Defensibility Standard', specification: 'Court-admissible analytical report documentation', standard: 'UK Civil Procedure Rules Part 35' }
    ],
    instrumentationAndPlatforms: [
      'Agilent 7890B GC with 5977B MSD and Pyrolysis Unit',
      'Waters ACQUITY Premier UPLC with QDa Mass Detector',
      'Thermo Nicolet iN10 MX FTIR Imaging Microscope',
      'Dionex ICS-6000 Ion Chromatography System'
    ],
    regulatoryCompliance: ['FDA Guidance on ANDA Q1/Q2 Sameness', 'MHRA Generic Medicine Similarity Rules', 'ISO 17025 Accredited Laboratory Testing'],
    clinicalSignificance: 'Enables generic drug developers to match reference listed drugs (RLDs) precisely, satisfying bioequivalence and regulatory approval criteria.',
    caseStudyOrApplication: {
      heading: 'Deformulation of Complex Topical Corticosteroid Cream',
      synopsis: 'A generic pharmaceutical client needed to achieve Q1/Q2 sameness with a market-leading commercial anti-inflammatory ointment.',
      outcomes: [
        'Identified all 12 excipients including subtle microcrystalline wax and emulsifier ratios',
        'Determined exact grades and molecular weights of cellulose polymers',
        'Generic formulation developed using this data matched physical rheology and passed bioequivalence testing'
      ]
    },
    contactFocus: 'Deformulation Projects & Q1/Q2 Reverse Engineering Inquiries'
  },
  {
    id: 'pharmaceutical-toxicology-services',
    slug: 'uk-science-pharmaceutical-toxicology-services',
    title: 'Pharmaceutical Toxicology Services & Safety Pharmacology',
    category: 'UK Science',
    subCategory: 'Preclinical Safety',
    heroBadge: 'GLP Toxicology & Safety',
    executiveSummary: 'Non-clinical toxicology testing, in vitro genetic toxicology, safety pharmacology screens, and toxicokinetic modeling supporting clinical trial authorisations.',
    leadParagraph: 'Evaluating non-clinical safety with scientific rigor. Our toxicology laboratories conduct GLP-compliant in vitro safety screens and non-clinical evaluations to identify organ toxicities and calculate human safety margins.',
    keyStats: [
      { label: 'GLP Audit Compliance', value: '100% Passed' },
      { label: 'Toxicology Screens/Yr', value: '450+ Assays' },
      { label: 'hERG Liability Screen', value: 'Automated Patch' },
      { label: 'Turnaround Time', value: '2–4 Weeks' }
    ],
    keyMethodologies: [
      {
        title: 'Cardiovascular Safety (Automated hERG Patch-Clamp)',
        description: 'Electrophysiological recording of human ether-à-go-go-related gene (hERG) potassium channels to screen for QT-interval prolongation risks.',
        tags: ['hERG', 'Cardiac Safety', 'Electrophysiology']
      },
      {
        title: 'In Vitro Genetic Toxicology Battery',
        description: 'Bacterial reverse mutation (Ames test) and in vitro micronucleus assays identifying mutagenic and clastogenic hazards.',
        tags: ['Ames Test', 'Genotox', 'Micronucleus']
      },
      {
        title: 'High-Content Hepatotoxicity Profiling',
        description: 'Multi-parametric cellular imaging evaluating mitochondrial membrane potential, ROS generation, and nuclear morphology in primary human hepatocytes.',
        tags: ['Hepatotoxicity', 'DILI', 'Primary Hepatocytes']
      }
    ],
    technicalSpecifications: [
      { parameter: 'hERG IC50 Determination', specification: '8-point concentration response curve, automated patch', standard: 'ICH S7B / CiPA Guidelines' },
      { parameter: 'Ames Test Bacterial Strains', specification: 'TA98, TA100, TA1535, TA1537, WP2uvrA (with/without S9)', standard: 'OECD Guideline 471' },
      { parameter: 'Micronucleus Cytotoxicity Index', specification: 'Relative population doubling (RPD) or CBPI index', standard: 'OECD Guideline 487' },
      { parameter: 'Toxicokinetic Sampling Limits', specification: 'Micro-sampling down to 20 µL whole blood', standard: 'ICH S3A Toxicokinetics' }
    ],
    instrumentationAndPlatforms: [
      'Sophion QPatch II Automated Electrophysiology System',
      'PerkinElmer Opera Phenix High-Content Imaging System',
      'SCIEX Triple Quad 6500+ LC-MS/MS for Toxicokinetics',
      'Automated Colony Counters for Ames Plate Reading'
    ],
    regulatoryCompliance: ['UK GLP Monitoring Programme (MHRA Verified)', 'OECD Principles of Good Laboratory Practice', 'ICH Safety Guidelines (S1–S11)', 'FDA 21 CFR Part 58'],
    clinicalSignificance: 'Prevents toxic compounds from reaching humans and establishes clear clinical monitoring parameters for dose escalation during Phase I studies.',
    caseStudyOrApplication: {
      heading: 'Early Cardiac Liability Identification in Lead Optimization',
      synopsis: 'Screening a series of 15 kinase inhibitors for potential QT interval prolongation before candidate selection.',
      outcomes: [
        'QPatch automated screening revealed sub-micromolar hERG inhibition in 8 of the 15 candidate molecules',
        'Structural modeling identified a specific basic amine interacting with the channel pore',
        'Synthetic analog devoid of the interaction maintained primary potency with hERG IC50 > 30 µM'
      ]
    },
    contactFocus: 'GLP Toxicology Packages & Safety Screening Contracts'
  },
  {
    id: 'polymer',
    slug: 'uk-science-polymer',
    title: 'Polymer Sciences & Biomaterial Engineering',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'Polymer Engineering',
    executiveSummary: 'Synthesis, functionalization, and biocompatibility screening of synthetic and bio-based polymers for targeted drug release and biomedical implants.',
    leadParagraph: 'Customizing polymer architecture for therapeutic delivery. Our polymer scientists design star polymers, block copolymers, and functionalized dendrimers tailored for specific biological environments.',
    keyStats: [
      { label: 'Polymer Architectures', value: 'Block, Star, Graft' },
      { label: 'Mw Control Precision', value: 'PDI < 1.15' },
      { label: 'Degradation Control', value: 'Days to Years' },
      { label: 'Biocompatibility', value: 'ISO 10993 Tested' }
    ],
    keyMethodologies: [
      {
        title: 'Reversible Addition-Fragmentation Transfer (RAFT)',
        description: 'Controlled radical polymerization producing well-defined amphiphilic block copolymers with narrow molecular weight distributions and targeted end-groups.',
        tags: ['RAFT', 'Polymerization', 'Controlled Radical']
      },
      {
        title: 'Ring-Opening Polymerization (ROP)',
        description: 'Organocatalyzed synthesis of biodegradable poly(lactic-co-glycolic acid) and polycaprolactone copolymers without metallic catalyst residues.',
        tags: ['ROP', 'Biodegradable', 'PLGA']
      },
      {
        title: 'Surface Functionalization & Bio-Conjugation',
        description: 'Click chemistry grafting of targeting ligands (peptides, antibodies, carbohydrates) onto polymer corona surfaces.',
        tags: ['Click Chemistry', 'Bioconjugation', 'Targeting']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Polymer Molecular Weight (Mn)', specification: '1,000 Da to 250,000 Da controlled range', standard: 'GPC/MALS Absolute Molecular Weight' },
      { parameter: 'Residual Monomer Limits', specification: '< 0.05% residual monomer via Headspace GC', standard: 'Ph. Eur. 2.4.24' },
      { parameter: 'Heavy Metal Catalyst Residue', specification: '< 1 ppm tin or transition metal residues', standard: 'ICP-MS / ICH Q3D' },
      { parameter: 'Endotoxin Contamination', specification: '< 0.1 EU/mg for injectable polymer grade', standard: 'USP <85> Bacterial Endotoxins' }
    ],
    instrumentationAndPlatforms: [
      'Agilent 1260 Infinity II Multi-Detector GPC/SEC System',
      'Radleys Carousel 12 Plus Parallel Polymer Synthesizer',
      'PerkinElmer Spectrum Two FTIR Spectrometer',
      'Mettler Toledo DSC 3+ Differential Scanning Calorimeter'
    ],
    regulatoryCompliance: ['ISO 10993 Biocompatibility Standards', 'USP <88> Biological Reactivity Tests in Vivo', 'ICH Q3D Elemental Impurities'],
    clinicalSignificance: 'Supplies reproducible, non-immunogenic polymeric carriers that protect unstable drugs, prolong half-life, and release payloads on demand.',
    caseStudyOrApplication: {
      heading: 'Metal-Free Synthesis of Injectable Sustained-Release PLGA',
      synopsis: 'A client required tin-free biodegradable PLGA copolymer for a delicate ophthalmological intravitreal implant.',
      outcomes: [
        'Developed an organocatalyzed ring-opening polymerization route eliminating stannous octoate catalyst',
        'Maintained precise 50:50 lactide:glycolide ratio with molecular weight of 25 kDa (PDI 1.12)',
        'Delivered 5 kg batch with undetectable tin levels (< 0.01 ppm) and zero ocular cytotoxicity'
      ]
    },
    contactFocus: 'Custom Polymer Synthesis & Biomaterial R&D Contracts'
  },
  {
    id: 'polymer-chemistry',
    slug: 'uk-science-polymer-chemistry',
    title: 'Polymer Chemistry & Hydrogel Architectures',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'Hydrogel & Network Chemistry',
    executiveSummary: 'Cross-linked hydrogel networks, responsive smart polymers, mucoadhesive formulations, and 3D tissue scaffolding matrices.',
    leadParagraph: 'Designing three-dimensional macromolecular networks that mimic human tissue mechanics or respond to environmental triggers like pH, temperature, and enzymatic cleavage.',
    keyStats: [
      { label: 'Hydrogel Swelling', value: 'Up to 5,000%' },
      { label: 'Elastic Modulus (G\')', value: '10 Pa to 50 kPa' },
      { label: 'Cross-Linking Methods', value: 'UV, Thermal, Enzymatic' },
      { label: 'Cytocompatibility', value: '> 95% Viability' }
    ],
    keyMethodologies: [
      {
        title: 'Photo-Crosslinked Hydrogel Synthesis',
        description: 'UV or blue-light induced cross-linking of methacrylated biopolymers (GelMA, HAMA) creating tunable viscoelastic hydrogels.',
        tags: ['GelMA', 'Photo-Crosslinking', 'Hydrogels']
      },
      {
        title: 'Stimuli-Responsive Hydrogel Networks',
        description: 'Synthesizing poly(NIPAM) and poly(acrylic acid) networks that undergo phase transitions at physiological body temperature or acidic tumor pH.',
        tags: ['Stimuli-Responsive', 'Smart Polymers', 'pH-Sensitive']
      },
      {
        title: 'Enzymatically Degradable Tissue Scaffolds',
        description: 'Incorporating matrix metalloproteinase (MMP) cleavage peptide sequences into synthetic networks to facilitate cellular ingrowth and tissue remodeling.',
        tags: ['Tissue Scaffolds', 'MMP Cleavable', 'Regenerative']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Rheological Storage Modulus (G\')', specification: 'Precision oscillatory shear from 0.01 to 100 Hz', standard: 'ASTM D4473 Rheology' },
      { parameter: 'Equilibrium Water Content', specification: '85% to 99% hydration capacity', standard: 'Gravimetric Swelling Analysis' },
      { parameter: 'Photo-Initiator Cytotoxicity', specification: '< 0.05% w/v LAP with > 95% cell viability', standard: 'ISO 10993-5 In Vitro Cytotoxicity' },
      { parameter: 'Pore Size Distribution', specification: '50 µm to 250 µm interconnected porosity', standard: 'Cryo-SEM Image Analysis' }
    ],
    instrumentationAndPlatforms: [
      'TA Instruments Discovery HR-30 Hybrid Rheometer',
      'Thorlabs Omnicure S2000 UV Curing System',
      'Hitachi FlexSEM 1000 II Low-Vacuum Cryo-SEM',
      'Biotek Synergy Neo2 Multi-Mode Cell Reader'
    ],
    regulatoryCompliance: ['ISO 10993-5 In Vitro Cytotoxicity Tests', 'ASTM F2150 Characterization of Biomaterial Scaffolds', 'GLP Compliant Biomaterial Testing'],
    clinicalSignificance: 'Enables regenerative medicine therapies, long-acting ophthalmic depots, and topical wound healing formulations that integrate naturally with host tissue.',
    caseStudyOrApplication: {
      heading: 'Injectable In Situ Gelling Hydrogel for Articular Cartilage Repair',
      synopsis: 'Designing a minimally invasive syringe-injectable formulation that cross-links rapidly in synovial joint spaces.',
      outcomes: [
        'Synthesized dual-cured hyaluronic acid network that solidifies within 90 seconds under mild illumination',
        'Maintained compressive modulus matching native cartilage (G\' = 35 kPa)',
        'Supported 98% chondrocyte viability and type II collagen deposition in 28-day 3D culture'
      ]
    },
    contactFocus: 'Hydrogel Development & Responsive Biomaterials Inquiries'
  },
  {
    id: 'safety-of-medicines',
    slug: 'uk-science-safety-of-medicines',
    title: 'Safety of Medicines & Pharmacovigilance',
    category: 'UK Science',
    subCategory: 'Regulatory & Governance',
    heroBadge: 'Pharmacovigilance & Safety',
    executiveSummary: 'Post-market safety surveillance, adverse event signal detection, Risk Management Plan (RMP) authoring, and Qualified Person for Pharmacovigilance (QPPV) services.',
    leadParagraph: 'Safeguarding patient safety throughout the therapeutic lifecycle. Our safety teams monitor clinical trial adverse events, execute real-world evidence surveillance, and author comprehensive periodic safety update reports (PSURs).',
    keyStats: [
      { label: 'Safety Reports Handled', value: '45,000+ Cases' },
      { label: 'MHRA Audit History', value: 'Zero Critical Findings' },
      { label: 'Signal Detection Frequency', value: 'Weekly Automated' },
      { label: 'QPPV Availability', value: '24/7 UK & EU' }
    ],
    keyMethodologies: [
      {
        title: 'Automated Disproportionality Signal Detection',
        description: 'Bayesian Confidence Propagation Neural Networks (BCPNN) and PRR calculations scanning global safety databases for emerging safety signals.',
        tags: ['Signal Detection', 'BCPNN', 'Adverse Events']
      },
      {
        title: 'Risk Management Plan (RMP) Authoring',
        description: 'Designing structured risk mitigation strategies, safety registries, and patient communication materials in full accordance with MHRA guidelines.',
        tags: ['RMP', 'Risk Mitigation', 'Patient Safety']
      },
      {
        title: 'Expedited & Periodic Regulatory Reporting',
        description: 'Processing ICSRs, SUSARs, and DSURs with electronic transmission directly to the MHRA and European Medicines Agency (EudraVigilance).',
        tags: ['ICSR', 'SUSAR', 'DSUR Reporting']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Expedited Reporting Timelines', specification: 'Fatal/life-threatening within 7 days; others within 15 days', standard: 'MHRA GPvP Regulations' },
      { parameter: 'Safety Database Architecture', specification: 'Oracle Argus Safety 21 CFR Part 11 compliant', standard: 'ICH E2B(R3) Data Standards' },
      { parameter: 'Literature Surveillance Scope', specification: 'Weekly indexing of Medline, Embase, and local journals', standard: 'EMA GVP Module VI' },
      { parameter: 'QPPV Resident Requirements', specification: 'Qualified Person permanently resident in the UK', standard: 'UK Statutory Instrument 2019/775' }
    ],
    instrumentationAndPlatforms: [
      'Oracle Argus Safety Enterprise Cloud System',
      'Biovia Safety Analytics & Data Mining Workbench',
      'MHRA Gateway / EudraVigilance Electronic EDI Hub',
      '24/7 Redundant Global Medical Information Helpline'
    ],
    regulatoryCompliance: ['UK Good Pharmacovigilance Practice (GPvP)', 'ICH E2A–E2F Safety Management Guidelines', 'EU Good Pharmacovigilance Practices (GVP) Modules', 'MHRA Vigilance Statutory Rules'],
    clinicalSignificance: 'Ensures that potential side effects are discovered, investigated, and addressed swiftly, protecting patients and maintaining market authorization.',
    caseStudyOrApplication: {
      heading: 'National Pharmacovigilance Setup for Newly Approved Biologic',
      synopsis: 'Establishing a turnkey UK pharmacovigilance system and QPPV oversight ahead of commercial product launch.',
      outcomes: [
        'Configured validated Oracle Argus safety database within 6 weeks',
        'Authored and submitted comprehensive UK Risk Management Plan accepted by MHRA without changes',
        'Maintained 100% on-time expedited reporting compliance across first year of patient use'
      ]
    },
    contactFocus: 'UK QPPV Services & Pharmacovigilance Contracting'
  },
  {
    id: 'devices-centre-of-excellence',
    slug: 'uk-science-devices-centre-of-excellence',
    title: 'Devices Centre of Excellence & Drug-Device Combinations',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'Medical Devices & Combination Products',
    executiveSummary: 'Development, verification, human factors engineering, and design controls for autoinjectors, pre-filled syringes, pen injectors, and digital inhalers.',
    leadParagraph: 'Combining advanced therapeutics with intuitive delivery hardware. Our medical devices center ensures drug-device combination products comply with ISO 13485 and MDR requirements while delivering seamless patient usability.',
    keyStats: [
      { label: 'Device Programs', value: '25+ Autoinjectors' },
      { label: 'ISO 13485 Audit', value: 'Certified Clean' },
      { label: 'Human Factors Tests', value: '1,500+ Participants' },
      { label: 'Injection Time Window', value: '< 10 Seconds' }
    ],
    keyMethodologies: [
      {
        title: 'Design Controls & Risk Management (ISO 14971)',
        description: 'Systematic Design History File (DHF) management, failure mode analysis (dFMEA, uFMEA), and verification testing cascades.',
        tags: ['Design Controls', 'ISO 14971', 'DHF']
      },
      {
        title: 'Formative & Summative Human Factors Engineering',
        description: 'Simulated-use usability evaluations assessing critical user tasks, needle safety features, and error-free autoinjector operation.',
        tags: ['Human Factors', 'Usability', 'Autoinjectors']
      },
      {
        title: 'Electromechanical Verification Testing',
        description: 'Automated test rigs measuring cap removal forces, injection stroke durations, needle extension depths, and activation click acoustics.',
        tags: ['Verification', 'Tensile Testing', 'Injection Dynamics']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Autoinjector Activation Force', specification: '15 N to 35 N controlled user activation', standard: 'ISO 11608-1 / ISO 11608-5' },
      { parameter: 'Delivered Dose Accuracy', specification: 'Within ± 5% of target volume for 1.0 mL and 2.25 mL syringes', standard: 'ISO 11608-1' },
      { parameter: 'Needle Shield Safety Lock', specification: '100% passive lockout post-injection', standard: 'ISO 23908 Sharps Injury Protection' },
      { parameter: 'Environmental Pre-Conditioning', specification: 'Cold drop testing, thermal cycling (-20°C to +60°C), vibration', standard: 'ASTM D4169 / ISO 11608' }
    ],
    instrumentationAndPlatforms: [
      'ZwickRoell Autoinjector Testing System with Acoustic Sensor',
      'High-Speed Video Motion Analysis Camera (10,000 fps)',
      'Simulated Usability Lab with One-Way Observation Mirrors',
      'Weiss Technik Environmental Climate Chambers'
    ],
    regulatoryCompliance: ['ISO 13485:2016 Medical Devices Quality Management', 'UK Medical Devices Regulations 2002 (UKCA Mark)', 'EU Medical Device Regulation (EU 2017/745 MDR Article 117)', 'FDA 21 CFR Part 820 / 21 CFR Part 4 (Combination Products)'],
    clinicalSignificance: 'Ensures that patients suffering from chronic illnesses can self-administer biological medicines reliably at home without dosage errors or needle-stick injuries.',
    caseStudyOrApplication: {
      heading: 'Human Factors Verification of 2.25 mL High-Viscosity Autoinjector',
      synopsis: 'Designing and validating a reusable autoinjector for a viscous (18 cP) biological drug product administered by elderly arthritis patients.',
      outcomes: [
        'Conducted summative usability study with 45 representative participants with zero critical use errors',
        'Verified average complete injection duration under 8.2 seconds across all temperatures',
        'Successfully submitted Article 117 Notified Body Opinion and MHRA marketing dossier'
      ]
    },
    contactFocus: 'Medical Device Development & Combination Product Testing'
  },
  {
    id: 'immunology',
    slug: 'uk-science-immunology',
    title: 'Immunology & Immunotherapy Research',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'Immunology Discovery',
    executiveSummary: 'Translational immunology investigating auto-reactive B-cells, checkpoint signaling, T-cell exhaustion, and targeted cytokine storm containment.',
    leadParagraph: 'Decoding the human immune system to tackle autoimmune pathologies and unlock anti-tumor responses. Our immunology research groups leverage primary human immune assays, high-dimensional flow cytometry, and cytokine arrays.',
    keyStats: [
      { label: 'Immunology Assets', value: '6 Pipeline Drugs' },
      { label: 'Flow Cytometry Channels', value: '48 Colors' },
      { label: 'Primary Immune Donors', value: '250+ Phenotyped' },
      { label: 'Immune Suppression Gain', value: '85% Cytokine Drop' }
    ],
    keyMethodologies: [
      {
        title: 'Multi-Color Spectral Phenotyping',
        description: 'High-parameter spectral flow cytometry resolving rare memory T-cell subsets, regulatory T-cells, and myeloid-derived suppressor populations.',
        tags: ['Spectral Flow', 'T-Cells', 'Phenotyping']
      },
      {
        title: 'Multiplex Cytokine Chemiluminescence',
        description: 'Quantifying up to 54 simultaneous cytokines, chemokines, and growth factors from minute serum or cell-culture supernatant volumes.',
        tags: ['Cytokines', 'Multiplex', 'Chemokines']
      },
      {
        title: 'Ex Vivo Human Mixed Lymphocyte Reactions (MLR)',
        description: 'Allogeneic and autologous co-culture assays testing checkpoint inhibitor reactivation and immunosuppressive biologic efficacy.',
        tags: ['MLR', 'Co-Culture', 'Ex Vivo']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Flow Cytometry Spectral Detection', specification: 'Full spectrum 355nm, 405nm, 488nm, 561nm, 640nm lasers', standard: 'ISAC Standards' },
      { parameter: 'Cytokine Dynamic Range', specification: '0.1 pg/mL to 10,000 pg/mL linearity', standard: 'Meso Scale Discovery Quality' },
      { parameter: 'Primary Cell Viability', specification: '> 90% viable post-cryopreservation thaw', standard: 'HTA Biobank SOPs' },
      { parameter: 'Regulatory T-Cell Purity', specification: 'CD4+ CD25+ FoxP3+ purity > 95%', standard: 'Cell Therapy Quality Standard' }
    ],
    instrumentationAndPlatforms: [
      'Cytek Aurora 5-Laser Spectral Flow Cytometer',
      'Meso Scale Discovery QuickPlex SQ 120 Platform',
      'Miltenyi Biotec autoMACS Pro Automated Cell Separator',
      'Incucyte S3 Live-Cell Analysis System'
    ],
    regulatoryCompliance: ['Human Tissue Authority (HTA) Licence', 'MHRA Good Clinical Practice for Clinical Bioassays', 'ISO 9001:2015 Research Quality'],
    clinicalSignificance: 'Translates biological discoveries into targeted immune-modulating drugs that can re-balance aberrant immune systems without broad systemic immunosuppression.',
    caseStudyOrApplication: {
      heading: 'Deconvoluting Cytokine Suppression by Bispecific mAb in SLE',
      synopsis: 'Evaluating a dual BAFF/APRIL inhibitor in primary B-cells isolated from systemic lupus erythematosus (SLE) patients.',
      outcomes: [
        'Demonstrated 88% selective reduction in auto-antibody secreting plasmablasts in vitro',
        'Preserved naive B-cell populations, reducing theoretical opportunistic infection risk',
        'Data formed the central scientific rationale for progressing asset BB-209 into Phase III clinical trials'
      ]
    },
    contactFocus: 'Immunology Collaborative Research & Assay Development'
  },
  {
    id: 'immunology-focus-areas',
    slug: 'uk-science-immunology-focus-areas',
    title: 'Immunology Focus Areas & Autoimmune Targets',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'Autoimmune & Inflammation',
    executiveSummary: 'Targeted research clusters focused on Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, and Multiple Sclerosis.',
    leadParagraph: 'Targeting the core biochemical drivers of chronic autoimmune conditions. We investigate tissue-specific inflammatory pathways, mucosal barrier integrity, and antigen-specific tolerance induction.',
    keyStats: [
      { label: 'Autoimmune Focus Areas', value: '4 Disease Suites' },
      { label: 'Patient Cohort Samples', value: '15,000 Biobanked' },
      { label: 'Target Engagement', value: 'Validated In Vitro' },
      { label: 'NHS Clinical Partners', value: '12 Medical Centers' }
    ],
    keyMethodologies: [
      {
        title: 'Intestinal Epithelial Barrier Models (Organ-on-Chip)',
        description: 'Microfluidic gut-on-a-chip platforms co-culturing primary human colon organoids with immune cells under mechanical peristalsis to study IBD.',
        tags: ['Organ-on-Chip', 'IBD', 'Gut Barrier']
      },
      {
        title: 'Synovial Fibroblast Inflammatory Profiling',
        description: 'Screening inhibitors of invasive synovial fibroblast phenotypes derived from joint replacements of rheumatoid arthritis patients.',
        tags: ['Rheumatoid Arthritis', 'Synovium', 'Fibroblasts']
      },
      {
        title: 'Antigen-Specific Immune Tolerance Assays',
        description: 'Engineering tolerogenic nanoparticles delivering myelin basic protein fragments to induce regulatory T-cells in MS models.',
        tags: ['Immune Tolerance', 'Multiple Sclerosis', 'Tolerogenic']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Barrier Electrical Resistance (TEER)', specification: '> 800 Ω·cm² in microfluidic epithelial chips', standard: 'Organ-on-Chip Standards' },
      { parameter: 'Organoid Cryopreservation Recovery', specification: '> 85% organoid reformation post-thaw', standard: 'Biobank Validation' },
      { parameter: 'Gene Expression Multiplexing', specification: 'NanoString nCounter 770-gene autoimmune panel', standard: 'NanoString Validated Assay' },
      { parameter: 'Ethical Consent Provenance', specification: '100% verified UK HTA ethics compliant', standard: 'UK Human Tissue Act 2004' }
    ],
    instrumentationAndPlatforms: [
      'Emulate Bio-O-System Organ-on-a-Chip Architecture',
      'NanoString nCounter SPRINT Profiler',
      'Leica SP8 Confocal Laser Scanning Microscope',
      'Automated Liquid Handling Workcell'
    ],
    regulatoryCompliance: ['Human Tissue Authority (HTA) Compliance', 'UK Clinical Research Network (CRN) Ethics Approvals', 'Good Research Practice (GRP)'],
    clinicalSignificance: 'Pinpoints actionable therapeutic nodes that halt chronic tissue destruction in autoimmune patients while sparing normal immune defense mechanisms.',
    caseStudyOrApplication: {
      heading: 'Restoring Epithelial Barrier Function in Ulcerative Colitis',
      synopsis: 'Evaluating a novel small-molecule kinase inhibitor on human gut organoid chips treated with pro-inflammatory TNF-alpha and IFN-gamma.',
      outcomes: [
        'Prevented loss of tight junction proteins (Claudin-1, ZO-1) under inflammatory challenge',
        'Restored epithelial barrier integrity by 92% compared to untreated control chips',
        'Initiated preclinical development for an oral locally released capsule formulation'
      ]
    },
    contactFocus: 'Autoimmune Disease Partnerships & Target Validation Inquiries'
  },
  {
    id: 'pioneers-in-science',
    slug: 'uk-science-pioneers-in-science',
    title: 'Pioneers in Science: Leadership & Scientific Advisory',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'Scientific Leadership',
    executiveSummary: 'Distinguished scientific leaders, Fellows of the Royal Society, and veteran drug developers driving our discovery and translational research programs.',
    leadParagraph: 'Scientific excellence guided by visionary leadership. Our Scientific Advisory Board and senior investigators bring decades of academic discovery and industrial drug development experience to our programs.',
    keyStats: [
      { label: 'Scientific Advisors', value: '14 Renowned Fellows' },
      { label: 'Cumulative Citations', value: '180,000+' },
      { label: 'Commercial Drugs Launched', value: '28 Medicines' },
      { label: 'Patents Held', value: '320+ Patents' }
    ],
    keyMethodologies: [
      {
        title: 'Translational Science Peer Review Panels',
        description: 'Rigorous internal scientific peer review evaluating project hypotheses, experimental design, and reproducibility before milestone stage-gates.',
        tags: ['Peer Review', 'Scientific Governance', 'Quality']
      },
      {
        title: 'Academic-Industry Fellowship Placements',
        description: 'Reciprocal postdoctoral fellow exchanges with leading UK research institutions including Cambridge, Oxford, and Imperial College London.',
        tags: ['Fellowships', 'Academia', 'Talent Exchange']
      },
      {
        title: 'Open Innovation Masterclasses',
        description: 'Quarterly symposia bringing together international leaders in structural biology, machine learning, and clinical pharmacology.',
        tags: ['Open Innovation', 'Symposia', 'Thought Leadership']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Scientific Governance Framework', specification: 'Quarterly SAB strategic project reviews', standard: 'Corporate Governance Code' },
      { parameter: 'Conflict of Interest Management', specification: 'Strict independence declarations across all advisory panels', standard: 'Nolan Principles of Public Life' },
      { parameter: 'Publications Ethics Policy', specification: 'Adherence to ICMJE guidelines for authorship', standard: 'ICMJE Recommendations' },
      { parameter: 'Research Data Archiving', specification: 'Long-term secure storage of all raw discovery records', standard: 'UKRI Data Management' }
    ],
    instrumentationAndPlatforms: [
      'Collaborative Research Knowledge Graph',
      'Enterprise Intellectual Property Management Hub',
      'Virtual Scientific Advisory Board Chamber',
      'Secure Data Sharing Cleanroom'
    ],
    regulatoryCompliance: ['UK Research and Innovation (UKRI) Ethics Standards', 'Royal Society of Chemistry Code of Conduct', 'Royal Society of Biology Ethical Standards'],
    clinicalSignificance: 'Ensures that discovery programs are steered by proven drug developers who have successfully converted laboratory theories into life-saving clinical realities.',
    caseStudyOrApplication: {
      heading: 'Advisory Board Intervention on Oncology Lead Optimization',
      synopsis: 'Strategic steering of an early immuno-oncology program facing chemical selectivity trade-offs.',
      outcomes: [
        'Advisory panel recommended a novel structural bio-isostere approach based on recent academic crystallographic insights',
        'Achieved a 400-fold boost in kinase target selectivity in the subsequent synthesis round',
        'Salvaged an asset that is currently preparing for Phase I trial authorization'
      ]
    },
    contactFocus: 'Scientific Advisory Board Inquiries & Academic Collaborations'
  },
  {
    id: 'developing-science-talent',
    slug: 'uk-science-developing-science-talent',
    title: 'Developing Science Talent: Fellowships & STEM',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'STEM Education & Skills',
    executiveSummary: 'Doctoral training partnerships, industrial biotechnology apprenticeships, and university talent incubators across Bedfordshire and the UK.',
    leadParagraph: 'Investing in the next generation of British scientific leaders. We partner with universities and colleges to offer fully funded PhD studentships, laboratory apprenticeships, and continuous professional training.',
    keyStats: [
      { label: 'Active PhD Students', value: '24 Sponsored' },
      { label: 'Apprentices Trained', value: '85+ Laboratory' },
      { label: 'STEM Outreach Reach', value: '5,000+ Students' },
      { label: 'Retention Post-Training', value: '92% Join Staff' }
    ],
    keyMethodologies: [
      {
        title: 'Industrial Doctorate Training Centres (IDTC)',
        description: 'Four-year funded PhD programs embedding university researchers within our active industrial bioprocessing and analytical cleanrooms.',
        tags: ['PhD Studentships', 'IDTC', 'Doctoral Training']
      },
      {
        title: 'Level 5 & 6 Laboratory Science Apprenticeships',
        description: 'Earn-while-you-learn degree apprenticeships providing hands-on training in cGMP manufacturing, chromatography, and cell culture.',
        tags: ['Apprenticeships', 'Laboratory Skills', 'cGMP Training']
      },
      {
        title: 'School & College STEM Discovery Camps',
        description: 'Interactive laboratory workshops inspiring secondary school students in Bedfordshire and London toward careers in life sciences.',
        tags: ['STEM Outreach', 'Youth Science', 'Community Engagement']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Apprenticeship Accreditation', specification: 'Institute for Apprenticeships and Technical Education (IfATE)', standard: 'UK National Standards' },
      { parameter: 'Mentorship Ratio', specification: '1:1 dedicated PhD scientist mentorship for every apprentice', standard: 'Internal Training Policy' },
      { parameter: 'Training Facility Safety', specification: 'Dedicated non-hazardous simulated training cleanroom', standard: 'HSE Educational Guidelines' },
      { parameter: 'Diversity & Inclusion Standard', specification: 'Equal opportunities monitoring across all fellowship cohorts', standard: 'Athena SWAN Aligned' }
    ],
    instrumentationAndPlatforms: [
      'Dedicated Educational Bioprocess Training Suite',
      'Virtual Reality Cleanroom Simulation Modules',
      'Analytical HPLC & PCR Training Workstations',
      'Digital Learning & Continuous Assessment Portal'
    ],
    regulatoryCompliance: ['Ofqual Educational Quality Standards', 'IfATE Laboratory Technician Standard', 'UK Science Council Registered Scientists (RSci)'],
    clinicalSignificance: 'Builds a resilient, highly trained domestic workforce required to power the UK’s expanding biomanufacturing and pharmaceutical sectors.',
    caseStudyOrApplication: {
      heading: 'Apprenticeship to Production Manager Progression Story',
      synopsis: 'A local school-leaver joined Bedfordshire Biotech on an Advanced Laboratory Apprentice program in 2019.',
      outcomes: [
        'Completed a fully funded BSc (Hons) in Applied Bioscience while working across our bioreactor suites',
        'Achieved Professional Registration as a Chartered Scientist (CSci)',
        'Now leads our downstream chromatography purification team of 8 scientists'
      ]
    },
    contactFocus: 'Fellowship Applications & University Partnership Programs'
  },
  {
    id: 'food-beverage',
    slug: 'uk-science-food-beverage',
    title: 'Food & Beverage Science: Nutrition & Purity Testing',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Food Safety & Bio-Nutrition',
    executiveSummary: 'Nutritional testing, allergen quantification, trace heavy metal analysis, pesticide residue screening, and novel food safety assessments.',
    leadParagraph: 'Applying pharmaceutical-grade analytical rigor to the food and beverage industry. We verify food safety, confirm nutritional label accuracy, and analyze novel functional ingredients and plant-based protein isolates.',
    keyStats: [
      { label: 'Food Samples Tested/Yr', value: '35,000+ Tests' },
      { label: 'Allergen Detection Limit', value: '< 1.0 ppm' },
      { label: 'Pesticide Screen Panel', value: '450+ Compounds' },
      { label: 'Turnaround Time', value: '48–72 Hours' }
    ],
    keyMethodologies: [
      {
        title: 'Multi-Residue Pesticide Screening (LC-MS/MS & GC-MS/MS)',
        description: 'QuEChERS extraction followed by tandem mass spectrometry identifying trace organophosphates, carbamates, and neonicotinoids.',
        tags: ['Pesticides', 'QuEChERS', 'Mass Spectrometry']
      },
      {
        title: 'Food Allergen Multiplex ELISA & PCR',
        description: 'Quantifying gluten, peanut, soy, dairy, and nut protein residues down to parts-per-million levels in complex food matrices.',
        tags: ['Allergens', 'ELISA', 'Food Safety']
      },
      {
        title: 'Nutritional Profiling & Heavy Metal Analysis',
        description: 'ICP-MS determination of arsenic, lead, cadmium, and mercury alongside fatty acid profiles and amino acid quantification.',
        tags: ['Heavy Metals', 'ICP-MS', 'Nutritional Labeling']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Pesticide Limit of Quantitation', specification: '< 0.01 mg/kg (EU/UK Maximum Residue Limits)', standard: 'SANTE/12682/2019 Guidance' },
      { parameter: 'Heavy Metal Sensitivity', specification: '< 0.005 mg/kg lead and cadmium', standard: 'Commission Regulation (EC) 1881/2006' },
      { parameter: 'Gluten Detection Limit', specification: '< 5 ppm gluten (certified gluten-free < 20 ppm)', standard: 'AOAC Official Method 2012.01' },
      { parameter: 'Microbiological Safety Testing', specification: 'Absence of Salmonella and Listeria in 25g sample', standard: 'ISO 6579 / ISO 11290' }
    ],
    instrumentationAndPlatforms: [
      'Agilent 6470 Triple Quadrupole LC-MS/MS System',
      'PerkinElmer NexION 2000 ICP-MS for Food Testing',
      'Bio-Rad Microplate Reader for Allergen ELISA',
      'Automated Dumas Protein Analyzer for Nitrogen Content'
    ],
    regulatoryCompliance: ['UK Food Standards Agency (FSA) Compliance', 'ISO 17025 Accredited Food Testing Laboratory', 'UKAS Schedule of Accreditation', 'Novel Foods Regulation (EU 2015/2283)'],
    clinicalSignificance: 'Protects consumer health by ensuring food products are free from hazardous allergens, toxic chemicals, and harmful microbiological contaminants.',
    caseStudyOrApplication: {
      heading: 'Validation of Novel Precision Fermentation Protein Ingredient',
      synopsis: 'A UK food-tech company required complete safety and purity testing for a recombinant milk protein produced by yeast fermentation.',
      outcomes: [
        'Confirmed absence of host cell DNA, antibiotic residues, and mycotoxins',
        'Verified amino acid profile matched bovine whey protein with 99.8% homology',
        'Data supported successful Novel Food authorization dossier submitted to the UK FSA'
      ]
    },
    contactFocus: 'Food Safety Testing & Nutritional Analysis Quotations'
  },
  {
    id: 'method-development-validation',
    slug: 'uk-science-method-development-validation',
    title: 'Method Development and Analytical Validation',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'ICH Q2(R2) Validation',
    executiveSummary: 'Development, optimization, and formal validation of HPLC, UHPLC, GC, and bioassay methods in strict adherence to ICH Q2(R2) guidelines.',
    leadParagraph: 'Designing dependable analytical methods that withstand regulatory inspection. We develop and validate custom chromatographic and spectroscopic testing protocols for drug substances, finished dosage products, and stability studies.',
    keyStats: [
      { label: 'Methods Validated', value: '520+ Protocols' },
      { label: 'Regulatory Acceptance', value: '100% Passed' },
      { label: 'Validation Protocols', value: 'ICH Q2(R2) / USP' },
      { label: 'Transfer Success', value: 'Right-First-Time' }
    ],
    keyMethodologies: [
      {
        title: 'Quality by Design (QbD) Method Development',
        description: 'Using experimental design (DoE) software to explore mobile phase pH, column chemistries, and gradient parameters to establish a robust method operating window.',
        tags: ['QbD', 'DoE', 'Chromatography']
      },
      {
        title: 'Full ICH Q2(R2) Analytical Validation',
        description: 'Rigorous assessment of specificity, linearity, accuracy, repeat precision, intermediate precision, LOD/LOQ, and robustness.',
        tags: ['ICH Q2(R2)', 'Validation', 'Precision & Accuracy']
      },
      {
        title: 'Analytical Method Transfer & Verification',
        description: 'Seamless protocol transfer to commercial manufacturing sites with comparative testing, pre-approved acceptance criteria, and transfer reports.',
        tags: ['Method Transfer', 'Verification', 'Tech Transfer']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Assay Linearity (R²)', specification: 'R² ≥ 0.999 across 50% to 150% target concentration', standard: 'ICH Q2(R2)' },
      { parameter: 'Repeatability Precision (% RSD)', specification: '< 1.0% RSD for active drug substance assay', standard: 'USP <1225>' },
      { parameter: 'Impurity Recovery Accuracy', specification: '95.0% to 105.0% spiked recovery at reporting threshold', standard: 'Ph. Eur. 2.2.46' },
      { parameter: 'Software Compliance', specification: 'Waters Empower 3 with full audit trails', standard: '21 CFR Part 11 / EU Annex 11' }
    ],
    instrumentationAndPlatforms: [
      'Waters ACQUITY Premier UPLC with PDA and QDa Detectors',
      'Agilent 1290 Infinity II 2D-LC Systems',
      'Thermo Vanquish Horizon UHPLC System',
      'Design-Expert DoE Method Optimization Software'
    ],
    regulatoryCompliance: ['ICH Q2(R2) Validation of Analytical Procedures', 'USP <1225> Validation of Compendial Procedures', 'FDA Analytical Procedures and Methods Validation Guidance', 'MHRA GxP Data Integrity Standards'],
    clinicalSignificance: 'Ensures that all clinical release and stability data is scientifically sound, reproducible, and defensible before regulatory inspectors.',
    caseStudyOrApplication: {
      heading: 'Stability-Indicating Assay for Degraded Oncology Injectable',
      synopsis: 'Developing a method capable of resolving 7 potential oxidative degradation products from an active cytotoxic peptide.',
      outcomes: [
        'Screened 8 stationary phases using automated column switching to find optimal resolution',
        'Resolved all 7 degradants with peak resolution factors > 2.2 in a 12-minute run',
        'Completed full ICH Q2(R2) validation package within 4 weeks, enabling immediate stability testing'
      ]
    },
    contactFocus: 'Analytical Method Development & Validation Inquiries'
  },
  {
    id: 'bedfordshire-biotech-uk',
    slug: 'uk-science-bedfordshire-biotech-uk',
    title: 'Bedfordshire Biotech UK: The Regional Hub',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'Greater London Life Sciences Hub',
    executiveSummary: 'The manufacturing anchor of the UK’s Golden Triangle, featuring 45,000 m² of physical cleanrooms, cold-chain logistics, and robotic manufacturing.',
    leadParagraph: 'Bridging the research discoveries of Oxford and Cambridge with industrial-scale biomanufacturing. Located within Greater London and minutes from London Luton Airport, our flagship campus provides the physical manufacturing infrastructure that keeps British science in the UK.',
    keyStats: [
      { label: 'Campus Footprint', value: '45,000 m²' },
      { label: 'Cleanroom Space', value: '18,500 m² cGMP' },
      { label: 'Airport Proximity', value: '18 Mins (Luton)' },
      { label: 'Clean Energy', value: '100% Renewable' }
    ],
    keyMethodologies: [
      {
        title: 'Golden Triangle Corridor Logistics',
        description: 'Daily direct courier links connecting our facility with University of Oxford discovery labs and Cambridge biomedical campus incubators.',
        tags: ['Golden Triangle', 'Oxford', 'Cambridge']
      },
      {
        title: 'Scalable Pilot-to-Commercial Cleanrooms',
        description: 'Multi-suite facility layout enabling clients to advance smoothly from 50L pilot trials to 2,000L commercial production runs under one roof.',
        tags: ['Cleanrooms', 'Scalability', 'Commercial cGMP']
      },
      {
        title: 'Integrated QC & QP Release Services',
        description: 'On-site analytical testing laboratories and resident Qualified Persons providing rapid batch release without third-party delays.',
        tags: ['QP Release', 'On-Site QC', 'Fast Release']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Cleanroom Classifications', specification: 'ISO Class 5, 7, 8 (Grade A, B, C, D cGMP suites)', standard: 'EU cGMP Annex 1 / ISO 14644' },
      { parameter: 'Power Redundancy', specification: 'Dual 11kV grid feeds with N+1 backup diesel generators', standard: 'Tier III Reliability' },
      { parameter: 'Pure Water Generation', specification: 'Continuous Water for Injection (WFI) loop at 85°C', standard: 'USP / Ph. Eur. WFI Monograph' },
      { parameter: 'Waste Decontamination', specification: 'Continuous thermal effluent inactivation system', standard: 'Environment Agency Permit' }
    ],
    instrumentationAndPlatforms: [
      'Flagship 45,000 m² Life Sciences Research Park Campus',
      'Cytiva Single-Use Bioreactor Cascades up to 2,000L',
      'Automated High-Speed Aseptic Vial Fill-Finish Lines',
      '24/7 Monitored Cryogenic Storage Vault'
    ],
    regulatoryCompliance: ['MHRA cGMP Manufacturing Authorisation MIA', 'MHRA Wholesale Distribution Authorisation WDA(H)', 'ISO 9001:2015 & ISO 14001:2015 Certified', 'Home Office Controlled Drugs Licences'],
    clinicalSignificance: 'Provides the vital physical bridge between academic discoveries and clinical treatments, preventing British spin-outs from having to seek manufacturing abroad.',
    caseStudyOrApplication: {
      heading: 'Cambridge Spin-Out Scaling First Clinical Batches',
      synopsis: 'A Cambridge gene-editing spin-out required urgent clinical trial manufacturing for a lead therapeutic candidate.',
      outcomes: [
        'Completed technology transfer into our Bedfordshire cleanrooms within 8 weeks',
        'Produced 3 consecutive engineering and cGMP batches meeting all target specifications',
        'Supplied patient treatment kits directly to Addenbrooke’s Hospital within 2 hours of release'
      ]
    },
    contactFocus: 'Facility Tours & Greater London Suite Reservation'
  },
  {
    id: 'company-facilities',
    slug: 'uk-science-company-facilities',
    title: 'Company Facilities & Infrastructure Tour',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'Physical Facilities',
    executiveSummary: 'An in-depth look at our specialized research labs, cleanrooms, high-containment suites, automated warehouses, and environmental monitoring systems.',
    leadParagraph: 'Built to pharmaceutical engineering standards. Our facilities combine intelligent building management systems, segregated air handling units, and strict personnel flow protocols to guarantee product sterility and data integrity.',
    keyStats: [
      { label: 'Total Building Area', value: '45,000 m²' },
      { label: 'HVAC Air Changes', value: 'Up to 60/Hour' },
      { label: 'Sensors Monitored', value: '4,200 Real-Time' },
      { label: 'Facility Uptime', value: '99.99%' }
    ],
    keyMethodologies: [
      {
        title: 'Cascade Pressure HVAC Segregation',
        description: 'Dedicated air handling units maintaining differential pressure cascades between cleanrooms to prevent cross-contamination.',
        tags: ['HVAC', 'Pressure Cascades', 'Segregation']
      },
      {
        title: 'Automated Facility Monitoring System (FMS)',
        description: 'Real-time 24/7 logging of temperature, relative humidity, differential pressure, and non-viable particulate counts.',
        tags: ['FMS', 'Real-Time Logging', 'Environmental Monitoring']
      },
      {
        title: 'Automated Guided Vehicle (AGV) Logistics',
        description: 'Robotic transport vehicles moving materials between warehouses and staging airlocks without human contamination risks.',
        tags: ['Robotics', 'Cleanroom Logistics', 'Automation']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Particulate Cleanroom Limits', specification: 'Zero particles ≥ 5.0 µm/m³ in Grade A laminar zones', standard: 'EU cGMP Annex 1' },
      { parameter: 'HEPA Filter Efficiency', specification: '99.995% at MPPS (H14 classification)', standard: 'EN 1822 Standards' },
      { parameter: 'Temperature Stability', specification: 'Controlled within ± 0.5°C in cleanrooms', standard: 'ISPE Baseline Guide' },
      { parameter: 'Access Security Protocols', specification: 'Biometric multi-factor authentication per zone', standard: '21 CFR Part 11 / ISO 27001' }
    ],
    instrumentationAndPlatforms: [
      'Siemens Desigo CC Integrated Building Management System',
      'Rotronic Environmental Monitoring Transmitters',
      'Steris VHP 1000ED Vaporized Hydrogen Peroxide Decontamination',
      'Automated High-Bay Cold Storage Warehouse'
    ],
    regulatoryCompliance: ['EU cGMP Annex 1 Cleanroom Standards', 'ISPE Baseline Pharmaceutical Engineering Guides', 'BREEAM Excellent Sustainable Building Certification', 'Health and Safety Executive (HSE) Workplace Rules'],
    clinicalSignificance: 'Ensures an uninterrupted, compliant environment where pharmaceuticals can be manufactured and tested with zero environmental contamination.',
    caseStudyOrApplication: {
      heading: 'Seamless Facility Expansion Without Production Interruption',
      synopsis: 'Constructing and commissioning a new 2,500 m² Grade B filling suite adjacent to active manufacturing areas.',
      outcomes: [
        'Employed temporary negative-pressure containment barriers during construction',
        'Zero particle or microbial excursions recorded in active adjoining cleanroom suites',
        'Commissioned and validated new suites 2 weeks ahead of scheduled audit date'
      ]
    },
    contactFocus: 'Site Audits & Physical Facility Verification Visits'
  },
  {
    id: 'global-regulatory-affairs',
    slug: 'uk-science-global-regulatory-affairs',
    title: 'Global Regulatory Affairs & Compliance Strategy',
    category: 'UK Science',
    subCategory: 'Regulatory & Governance',
    heroBadge: 'Global Regulatory Strategy',
    executiveSummary: 'Navigating international regulatory requirements with the MHRA, EMA, FDA, PMDA, and Health Canada to secure accelerated market approvals.',
    leadParagraph: 'Connecting scientific data with regulatory approval. Our regulatory affairs experts author eCTD dossiers, lead agency scientific advice meetings, and craft regulatory strategies that shorten review timelines for novel therapeutics.',
    keyStats: [
      { label: 'Dossiers Submitted', value: '65+ eCTD' },
      { label: 'Agency Clearance', value: '100% First-Cycle' },
      { label: 'Global Markets Covered', value: 'UK, US, EU, JP' },
      { label: 'Fast-Track Badges', value: 'ILAP, Fast Track, PRIME' }
    ],
    keyMethodologies: [
      {
        title: 'Accelerated Pathway Applications (ILAP, PRIME, Breakthrough)',
        description: 'Securing fast-track regulatory designations that offer priority review and frequent scientific dialogue with health authorities.',
        tags: ['ILAP', 'PRIME', 'Breakthrough Designation']
      },
      {
        title: 'Full eCTD Module 1–5 Authoring & Publishing',
        description: 'Drafting comprehensive Quality (CMC), Non-clinical, and Clinical dossiers formatted to stringent electronic filing standards.',
        tags: ['eCTD', 'CMC', 'Dossier Publishing']
      },
      {
        title: 'Health Authority Meeting Representation',
        description: 'Preparing briefing books and leading scientific advice discussions with the MHRA, FDA (Type B/C), and EMA scientific panels.',
        tags: ['Scientific Advice', 'FDA Meetings', 'MHRA Advice']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Electronic Dossier Standard', specification: 'eCTD v4.0 and v3.2.2 compliance', standard: 'ICH M8 Electronic Standards' },
      { parameter: 'Regulatory Response Timelines', specification: 'Health authority queries resolved within 5 business days', standard: 'Internal QA SOP' },
      { parameter: 'CMC Regulatory Gap Analysis', specification: 'Comprehensive audit against ICH Q8, Q9, Q10, Q11', standard: 'ICH Quality Guidelines' },
      { parameter: 'Validation Check Threshold', specification: '100% pass on Lorenz and Extedo validation checkers', standard: 'FDA / EMA eCTD Specifications' }
    ],
    instrumentationAndPlatforms: [
      'Extedo eCTDmanager Publishing Suite',
      'Lorenz docuBridge Regulatory Publishing Engine',
      'MasterControl Regulatory Document Repository',
      'Secure Electronic Health Authority Gateways (ESG)'
    ],
    regulatoryCompliance: ['ICH Guidelines (M4, M8, Q, S, E Series)', 'MHRA Guidance on UK Licencing Procedures', 'FDA 21 CFR Part 312 (IND) & Part 314 (NDA)', 'EU Directive 2001/83/EC'],
    clinicalSignificance: 'Ensures that promising experimental medicines reach patients faster by eliminating regulatory deficiencies and communication delays with health authorities.',
    caseStudyOrApplication: {
      heading: 'Simultaneous Tri-Region CTA/IND Authorisation for Biologic',
      synopsis: 'Filing clinical trial applications simultaneously with the UK MHRA, US FDA, and European EMA for a Phase I autoimmune study.',
      outcomes: [
        'Authored harmonized CMC and non-clinical dossier modules acceptable across all three jurisdictions',
        'Cleared all three agencies within 30 days without any clinical hold queries',
        'Initiated international clinical trial on the exact target launch date'
      ]
    },
    contactFocus: 'Regulatory Affairs Strategy & eCTD Dossier Consulting'
  },
  {
    id: 'capabilities',
    slug: 'uk-science-capabilities',
    title: 'UK Capabilities: Research & Commercial Services',
    category: 'UK Science',
    subCategory: 'Platform Technologies',
    heroBadge: 'End-to-End Capabilities',
    executiveSummary: 'An overview of our integrated scientific, analytical, biomanufacturing, and regulatory capabilities supporting UK and international partners.',
    leadParagraph: 'Operating as a comprehensive life sciences partner. From early target discovery through to commercial product supply, our UK teams provide the expertise and infrastructure necessary to advance medicines at every phase.',
    keyStats: [
      { label: 'Capabilities Catalog', value: '45+ Disciplines' },
      { label: 'Active Partner Projects', value: '110+ Live' },
      { label: 'Client Satisfaction', value: '99.4%' },
      { label: 'On-Time Delivery', value: '98.8%' }
    ],
    keyMethodologies: [
      {
        title: 'Full Lifecycle Partnership Model',
        description: 'Single-source contractual integration covering discovery, preformulation, analytical testing, cGMP production, and clinical trial packaging.',
        tags: ['Full Lifecycle', 'Integrated Services', 'End-to-End']
      },
      {
        title: 'Cross-Disciplinary Project Teams',
        description: 'Each client project is assigned a dedicated team of chemists, biologists, analytical scientists, and project managers under a single point of contact.',
        tags: ['Project Management', 'Dedicated Teams', 'Agile']
      },
      {
        title: 'Transparent Real-Time Client Portal',
        description: 'Secure digital access to batch records, analytical data, stability charts, and project milestones via our cloud-based LIMS portal.',
        tags: ['Client Portal', 'Transparency', 'Data Access']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Quality Management Certification', specification: 'ISO 9001:2015 and cGMP accreditation', standard: 'UKAS / MHRA Verified' },
      { parameter: 'Project Milestone Reporting', specification: 'Bi-weekly teleconferences and formal written sprint reports', standard: 'PMI Standards' },
      { parameter: 'Intellectual Property Protection', specification: '100% of generated project IP assigned to the client', standard: 'UK Contract Law' },
      { parameter: 'Audit Availability', specification: 'Full on-site and virtual client audit access', standard: 'GxP Audit Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Comprehensive Suite of 45,000 m² Facilities',
      'Enterprise Integrated LIMS & ERP Architecture',
      'Secure Client Collaboration & Document Portal',
      'Advanced High-Throughput Analytical Instrumentation'
    ],
    regulatoryCompliance: ['MHRA GxP Standards across all operations', 'ISO 9001:2015 Quality Management Systems', 'UK Data Protection Act 2018 / UK GDPR', 'Health and Safety Executive (HSE) Regulations'],
    clinicalSignificance: 'Eliminates friction and delays caused by managing multiple disparate contract research and manufacturing organizations, speeding clinical progress.',
    caseStudyOrApplication: {
      heading: 'Turnkey Clinical Delivery for Virtual Biotech Sponsor',
      synopsis: 'A virtual UK biotech company required complete development and clinical supply execution for their lead cancer asset.',
      outcomes: [
        'Managed formulation, analytical validation, cGMP manufacturing, and trial packaging seamlessly',
        'Delivered complete Phase I clinical supplies directly to clinical trial sites on schedule',
        'Client subsequently achieved a £45M Series B funding round on the back of trial data'
      ]
    },
    contactFocus: 'Commercial Capability Review & Partnership Scoping'
  },
  {
    id: 'bedfordshire-biotech-worldwide',
    slug: 'uk-science-bedfordshire-biotech-worldwide',
    title: 'Bedfordshire Biotech Worldwide: Global Footprint',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'Global Reach & Liaison',
    executiveSummary: 'International operations, US corporate liaison, global distribution networks, and cross-border research collaborations.',
    leadParagraph: 'Rooted in the United Kingdom, operating across the world. Bedfordshire Biotech partners with biopharmaceutical innovators across North America, Europe, and the Asia-Pacific region, providing seamless international supply and regulatory support.',
    keyStats: [
      { label: 'International Markets', value: '85+ Countries' },
      { label: 'US Liaison Presence', value: 'Active Operations' },
      { label: 'Global Clinical Sites', value: '180+ Supported' },
      { label: 'GDP Cold-Chain Reach', value: 'Worldwide' }
    ],
    keyMethodologies: [
      {
        title: 'Transatlantic Regulatory Bridge',
        description: 'Harmonizing UK MHRA and US FDA regulatory filings to enable simultaneous clinical development across both major territories.',
        tags: ['Transatlantic', 'MHRA & FDA', 'Harmonization']
      },
      {
        title: 'International GDP Cold-Chain Network',
        description: 'Validated global shipping lanes utilizing dry vapor cryogenic shippers and thermal tracking to reach hospitals across 85 countries.',
        tags: ['Global Logistics', 'Cold-Chain', 'GDP']
      },
      {
        title: 'Cross-Border Research Consortia',
        description: 'Active collaboration in international scientific alliances, global health initiatives, and rare disease research networks.',
        tags: ['Consortia', 'Global Health', 'Rare Diseases']
      }
    ],
    technicalSpecifications: [
      { parameter: 'International Quality Standards', specification: 'Harmonized compliance with ICH, WHO, and PIC/S standards', standard: 'PIC/S GMP Guide' },
      { parameter: 'Customs & Export Compliance', specification: 'Full Authorized Economic Operator (AEO) status', standard: 'HMRC Customs Standards' },
      { parameter: 'Currency & Commercial Flexibility', specification: 'Contracting in GBP, USD, EUR, and JPY', standard: 'International Banking' },
      { parameter: 'Time-Zone Overlap', specification: 'Dedicated teams providing 24/7 global support coverage', standard: 'Enterprise SLA' }
    ],
    instrumentationAndPlatforms: [
      'Global Telemetric Supply Chain Tracking Command Center',
      'Multi-Currency ERP & Financial Management Suite',
      'International Regulatory Filing Architecture',
      'Secure Global Client Communication Portal'
    ],
    regulatoryCompliance: ['PIC/S (Pharmaceutical Inspection Co-operation Scheme)', 'WHO Good Distribution Practices', 'US FDA Foreign Inspection Standards', 'UK Department for Business and Trade (DBT) Guidelines'],
    clinicalSignificance: 'Ensures that medical advances originating in the UK can be scaled and distributed internationally to treat patients across the globe.',
    caseStudyOrApplication: {
      heading: 'Simultaneous Clinical Batch Supply to 22 Global Trial Sites',
      synopsis: 'Deploying a fragile cryogenic cellular therapy to investigational centers in the UK, US, Germany, and Australia.',
      outcomes: [
        'Maintained 100% temperature integrity (< -150°C) across all shipments via real-time GPS telemetry',
        'Zero customs holds or border delays experienced across 44 international shipments',
        'All patient doses administered within protocol-specified clinical stability windows'
      ]
    },
    contactFocus: 'International Business Development & Overseas Inquiries'
  },
  {
    id: 'areas-of-focus',
    slug: 'uk-science-areas-of-focus',
    title: 'Areas of Focus & Therapeutic Specialisations',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'Therapeutic Pillars',
    executiveSummary: 'Specialized focus across Oncology, Autoimmune Disorders, Rare Genetic Diseases, Metabolic Health, and Infectious Disease Resilience.',
    leadParagraph: 'Concentrating our scientific firepower where patient need is greatest. Bedfordshire Biotech targets therapeutic areas with high unmet clinical burdens, leveraging deep mechanistic understanding to build transformative treatments.',
    keyStats: [
      { label: 'Therapeutic Pillars', value: '5 Core Areas' },
      { label: 'Preclinical Assets', value: '18 Molecules' },
      { label: 'Clinical Stage Assets', value: '4 Programs' },
      { label: 'Unmet Need Index', value: 'High Priority' }
    ],
    keyMethodologies: [
      {
        title: 'Precision Oncology & Targeted Biologics',
        description: 'Developing bispecific antibodies and antibody-drug conjugates (ADCs) targeting tumor-specific antigens with minimal healthy tissue toxicity.',
        tags: ['Oncology', 'ADCs', 'Bispecifics']
      },
      {
        title: 'Orphan & Rare Genetic Disease Platforms',
        description: 'Utilizing mRNA lipid nanoparticles and recombinant enzyme replacement to treat rare metabolic and lysosomal storage disorders.',
        tags: ['Rare Diseases', 'mRNA', 'Enzyme Replacement']
      },
      {
        title: 'Metabolic & Fibrotic Disease Modeling',
        description: 'Targeting non-alcoholic steatohepatitis (NASH/MASH) and pulmonary fibrosis through anti-fibrotic signaling modulators.',
        tags: ['Fibrosis', 'MASH', 'Metabolic']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Therapeutic Modalities Explored', specification: 'mAbs, bispecifics, recombinant proteins, mRNA LNPs, small molecules', standard: 'Multi-Modality Platform' },
      { parameter: 'Target Selection Validation', specification: 'Human genetic linkage evidence required for all targets', standard: 'Genomic Target Selection' },
      { parameter: 'Biomarker Stratification', specification: 'Companion diagnostic feasibility assessed from Discovery', standard: 'Precision Medicine Policy' },
      { parameter: 'Ethical Review Criteria', specification: 'Strict clinical risk-benefit threshold evaluation', standard: 'Declaration of Helsinki' }
    ],
    instrumentationAndPlatforms: [
      'Multi-Modality Bioprocessing & Analytical Infrastructure',
      'Automated High-Throughput Target Validation Workstations',
      'Advanced Flow Cytometry & Molecular Profiling Suites',
      'Translational Disease Phenotyping Biobank'
    ],
    regulatoryCompliance: ['MHRA Orphan Medicinal Product Designations', 'FDA Orphan Drug Act Compliance', 'EMA Committee for Orphan Medicinal Products (COMP)'],
    clinicalSignificance: 'Ensures research investments focus on validated disease targets that offer transformative therapeutic improvements over existing standards of care.',
    caseStudyOrApplication: {
      heading: 'Orphan Drug Designation for Rare Lysosomal Disorder Asset',
      synopsis: 'Advancing asset BB-318 (recombinant alpha-galactosidase A mRNA) through preclinical proof-of-concept for Fabry disease.',
      outcomes: [
        'Demonstrated complete clearance of toxic cellular storage deposits in patient-derived kidney cells',
        'Secured MHRA and FDA Orphan Drug Designation status',
        'Initiated Phase I clinical trial setup across 4 European specialist metabolic hospitals'
      ]
    },
    contactFocus: 'Therapeutic Area Collaboration & In-Licensing Opportunities'
  },
  {
    id: 'medicines-donations',
    slug: 'uk-science-medicines-donations',
    title: 'Medicines Donations & Humanitarian Supply',
    category: 'UK Science',
    subCategory: 'Regulatory & Governance',
    heroBadge: 'Global Humanitarian Support',
    executiveSummary: 'Philanthropic supply programs, emergency medicine relief donations, and partnerships with global humanitarian health organizations.',
    leadParagraph: 'Expanding global access to essential medicines. We partner with the World Health Organization, non-governmental organizations, and international charities to donate high-quality medicines to underserved communities and crisis zones.',
    keyStats: [
      { label: 'Doses Donated', value: '2.5M+ Treatments' },
      { label: 'Partner Charities', value: '18 Global NGOs' },
      { label: 'Crisis Deployments', value: '12 Emergency Reliefs' },
      { label: 'Quality Standard', value: '100% cGMP' }
    ],
    keyMethodologies: [
      {
        title: 'WHO Guidelines on Medicines Donations Adherence',
        description: 'Strict adherence to international guidelines ensuring all donated products have valid shelf-life (> 12 months) and approved labeling.',
        tags: ['WHO Guidelines', 'Humanitarian', 'Donations']
      },
      {
        title: 'Rapid Emergency Relief Deployment',
        description: 'Pre-packaged emergency response medical kits maintained in temperature-controlled warehouses ready for dispatch within 24 hours of crises.',
        tags: ['Emergency Relief', 'Disaster Response', 'Cold-Chain']
      },
      {
        title: 'Traceability & Anti-Diversion Protocols',
        description: 'End-to-end serialized barcode tracking ensuring donated medicines reach genuine healthcare facilities without commercial diversion.',
        tags: ['Anti-Diversion', 'Serialization', 'Traceability']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Minimum Shelf-Life on Dispatch', specification: 'At least 12 months remaining shelf-life upon receipt', standard: 'WHO Medicines Donations Guidelines' },
      { parameter: 'Packaging & Labeling', specification: 'Multi-lingual emergency labeling and tamper-evident packaging', standard: 'International Humanitarian Standards' },
      { parameter: 'Transport Cold-Chain Monitoring', specification: 'Continuous single-use temperature loggers included in each pallet', standard: 'GDP Humanitarian Standards' },
      { parameter: 'Customs Clearance Documentation', specification: 'Pre-cleared donation certificates and diplomatic waivers', standard: 'UNOCHA Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Dedicated Humanitarian Supply Logistics Staging Area',
      'Automated Serialization & Verification Aggregation Line',
      '24/7 Crisis Dispatch Coordination Command Center',
      'Validated Temperature-Controlled Emergency Air Freight Kits'
    ],
    regulatoryCompliance: ['WHO Guidelines for Medicine Donations (Revised 2011)', 'MHRA Export Authorisations for Humanitarian Aid', 'UN International Health Regulations', 'UK Charity Commission Standards'],
    clinicalSignificance: 'Provides life-saving medications to vulnerable populations facing natural disasters, conflict zones, or acute healthcare infrastructure collapses.',
    caseStudyOrApplication: {
      heading: 'Emergency Supply of Sterile Injectable Antibiotics to Flood Crisis',
      synopsis: 'Deploying 150,000 vials of essential sterile antibiotics to international emergency clinics following catastrophic flooding.',
      outcomes: [
        'Assembled and dispatched 45 pallets with active temperature logging within 36 hours of NGO call',
        'Completed customs transit without delays via diplomatic air clearance links',
        'Directly supported treatment of over 40,000 displaced patients in temporary field hospitals'
      ]
    },
    contactFocus: 'Humanitarian Partnerships & Medicines Donation Inquiries'
  },
  {
    id: 'bedfordshire-biotech-field-pipeline',
    slug: 'uk-science-bedfordshire-biotech-field-pipeline',
    title: 'Bedfordshire Biotech Field Pipeline: Clinical & Preclinical Assets',
    category: 'UK Science',
    subCategory: 'Clinical Development',
    heroBadge: 'Active Therapeutic Pipeline',
    executiveSummary: 'An overview of our proprietary pipeline assets across oncology, immunology, genetics, metabolic disorders, and neuroscience.',
    leadParagraph: 'A diversified clinical pipeline engineered for high impact. From gene-editing therapies in Phase II trials to early discovery targets, our pipeline reflects our commitment to addressing severe human diseases.',
    keyStats: [
      { label: 'Total Pipeline Assets', value: '18 Compounds' },
      { label: 'Clinical Phase Assets', value: '4 in Clinic' },
      { label: 'Lead Asset (BB-209)', value: 'Phase III Trial' },
      { label: 'Partnered Co-Devs', value: '8 Programs' }
    ],
    keyMethodologies: [
      {
        title: 'Multi-Modality Pipeline Architecture',
        description: 'Balancing small molecules, monoclonal antibodies, bispecifics, and gene-editing platforms to minimize platform-specific biological risk.',
        tags: ['Multi-Modality', 'Pipeline', 'Risk Balancing']
      },
      {
        title: 'Accelerated Clinical Proof-of-Concept',
        description: 'Deploying sensitive biomarker readouts early in Phase I trials to demonstrate biological target engagement ahead of Phase II expansion.',
        tags: ['Proof-of-Concept', 'Biomarkers', 'Phase I']
      },
      {
        title: 'Strategic Licensing & Co-Development',
        description: 'Partnering selected pipeline candidates with multinational pharmaceutical companies for late-stage global commercialization.',
        tags: ['Licensing', 'Co-Development', 'Commercialization']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Lead Asset BB-104', specification: 'Cas12-Treg Ultra (CRISPR Gene Edit) in Phase II AML trial', standard: 'MHRA CTA Authorised' },
      { parameter: 'Lead Asset BB-209', specification: 'VisiMab Bispecific (BAFF/APRIL mAb) in Phase III Lupus trial', standard: 'Global Pivotal Trial' },
      { parameter: 'Lead Asset BB-318', specification: 'Lipo-Enzyme Alpha (mRNA LNP) in Phase I Fabry disease trial', standard: 'First-in-Human Completed' },
      { parameter: 'Lead Asset BB-412', specification: 'GlucoReg-X (Recombinant Enzyme) in Phase II MASH fibrosis trial', standard: 'Pivotal Phase II Active' }
    ],
    instrumentationAndPlatforms: [
      'Proprietary Clinical Data Management Portal',
      'Pipeline Tracking & Milestone Analytics Hub',
      'Central Clinical Trial Biobanking Facility',
      'Advanced High-Throughput Screening Suites'
    ],
    regulatoryCompliance: ['ICH E6(R2) Good Clinical Practice (GCP)', 'MHRA Clinical Trial Authorisations (CTA)', 'FDA Investigational New Drug (IND) Approvals', 'EMA Clinical Trials Regulation (CTR)'],
    clinicalSignificance: 'Translates laboratory insights into tangible, clinically validated medicines that change survival outcomes for patients with serious diseases.',
    caseStudyOrApplication: {
      heading: 'Phase II Milestone Achievement for CRISPR Candidate BB-104',
      synopsis: 'Evaluating clinical remission rates and safety in refractory acute myeloid leukemia patients treated with site-directed epigenetic silencing.',
      outcomes: [
        'Achieved complete morphological remission in 64% of evaluable patients in cohort 2',
        'Zero grade 4 off-target toxicity or cytokine storm events observed',
        'Received MHRA Innovation Passport and FDA Fast Track status to accelerate Phase III setup'
      ]
    },
    contactFocus: 'Pipeline Licensing & Clinical Co-Development Inquiries'
  },
  {
    id: 'counterfeit-medicines',
    slug: 'uk-science-counterfeit-medicines',
    title: 'Counterfeit Medicines: Detection & Forensics',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Anti-Counterfeit Forensics',
    executiveSummary: 'Detecting counterfeit drugs, sub-standard medicines, diverted stock, and falsified active pharmaceutical ingredients.',
    leadParagraph: 'Combating the growing global threat of falsified medicines. Our forensic laboratories deploy handheld spectroscopy, mass spectrometry, and packaging inspection to authenticate suspect pharmaceuticals.',
    keyStats: [
      { label: 'Suspect Batches Tested', value: '1,400+ Lots' },
      { label: 'Falsified Rate Found', value: '18% Confirmed Fake' },
      { label: 'Handheld Raman Scan', value: '< 15 Seconds' },
      { label: 'Law Enforcement Cases', value: '42 Supported' }
    ],
    keyMethodologies: [
      {
        title: 'Handheld Raman & NIR Field Identification',
        description: 'Through-barrier non-destructive spectroscopic scanning identifying counterfeit pills and ampoules without opening packaging.',
        tags: ['Handheld Raman', 'NIR', 'Non-Destructive']
      },
      {
        title: 'Mass Spectrometric Impurity Fingerprinting',
        description: 'High-resolution Orbitrap mass spectrometry identifying incorrect APIs, toxic adulterants, and industrial solvent residues.',
        tags: ['Mass Spec', 'Adulterants', 'Toxicology']
      },
      {
        title: 'Microscopic Packaging & Hologram Verification',
        description: 'Forensic microscopic examination of security inks, micro-printing, tamper-evident seals, and 2D barcode serialisation numbers.',
        tags: ['Packaging Forensics', 'Holograms', 'Serialisation']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Spectroscopic Verification Library', specification: '> 30,000 verified authentic pharmaceutical spectral profiles', standard: 'ASTM E1840 Raman Standard' },
      { parameter: 'Detection of Trace Adulterants', specification: '< 0.001% w/w detection limit for toxic contaminants', standard: 'GLP Forensic Methods' },
      { parameter: 'Chain of Custody Documentation', specification: 'Court-admissible tamper-evident evidence management', standard: 'ISO 17025 Forensic Testing' },
      { parameter: 'Barcode Falsification Check', specification: 'Verification against national medicine verification systems (NMVS)', standard: 'FMD / DSCSA Verification' }
    ],
    instrumentationAndPlatforms: [
      'Rigaku Progeny Handheld 1064nm Raman Analyzer',
      'Thermo Scientific Q Exactive Focus Orbitrap LC-MS/MS',
      'Keyence VHX-7000 Digital Forensic Microscope',
      'Foster & Freeman VSC 8000 Document Examination System'
    ],
    regulatoryCompliance: ['Falsified Medicines Directive (Directive 2011/62/EU)', 'UK Falsified Medicines Regulations', 'ISO 17025 Forensic Testing Standards', 'Interpol & MHRA Enforcement Partnership'],
    clinicalSignificance: 'Protects patients from lethal adulterated drugs and preserves public trust in genuine, licensed pharmaceuticals.',
    caseStudyOrApplication: {
      heading: 'Isolation of Toxic Industrial Solvent in Counterfeit Weight-Loss Injections',
      synopsis: 'Analyzing suspect pre-filled pens seized by UK enforcement agencies displaying suspicious labeling and clouded solutions.',
      outcomes: [
        'Handheld Raman and LC-MS proved complete absence of authentic GLP-1 peptide API',
        'Identified high levels of toxic ethylene glycol and heavy metal contamination in formulation',
        'Provided evidence supporting national public health warnings and swift criminal prosecution'
      ]
    },
    contactFocus: 'Anti-Counterfeit Testing & Forensic Investigation Inquiries'
  },
  {
    id: 'reporting-side-effects',
    slug: 'uk-science-reporting-side-effects',
    title: 'Reporting Side Effects & Patient Safety Reporting',
    category: 'UK Science',
    subCategory: 'Regulatory & Governance',
    heroBadge: 'Patient Safety & Yellow Card',
    executiveSummary: 'Patient and physician adverse event reporting, MHRA Yellow Card integration, medical safety evaluation, and 24/7 pharmacovigilance hotlines.',
    leadParagraph: 'Ensuring every patient voice is heard. We operate accessible adverse event reporting portals and 24/7 medical information helplines, ensuring all side-effect reports are investigated and submitted to health authorities.',
    keyStats: [
      { label: 'Hotline Availability', value: '24/7 / 365 Days' },
      { label: 'Report Intake Time', value: '< 24 Hours' },
      { label: 'MHRA Yellow Card', value: 'Direct Integration' },
      { label: 'Medical Follow-Up', value: '100% of Cases' }
    ],
    keyMethodologies: [
      {
        title: 'Multi-Channel Adverse Event Intake',
        description: 'Secure digital intake portals, mobile web reporting forms, and telephone lines staffed by qualified healthcare professionals.',
        tags: ['Multi-Channel', 'Patient Portals', 'Intake']
      },
      {
        title: 'MHRA Yellow Card Scheme Harmonization',
        description: 'Seamless integration with the UK Yellow Card system, ensuring electronic transmission of patient-reported safety signals.',
        tags: ['Yellow Card', 'MHRA', 'Safety Surveillance']
      },
      {
        title: 'Physician-Led Medical Causality Assessment',
        description: 'Board-certified medical doctors reviewing every adverse drug reaction report to determine potential product causality.',
        tags: ['Medical Review', 'Causality', 'Patient Safety']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Adverse Event Logging Window', specification: 'Within 24 hours of first notification receipt', standard: 'MHRA GPvP Module VI' },
      { parameter: 'Call Center SLA', specification: '95% of calls answered within 20 seconds by medical specialists', standard: 'ISO 18295 Standards' },
      { parameter: 'Patient Privacy Protection', specification: 'Full anonymization complying with UK GDPR and Data Protection Act', standard: 'UK GDPR / Caldicott Principles' },
      { parameter: 'Expedited Submission Timeline', specification: 'Serious reports transmitted to MHRA within 15 calendar days', standard: 'ICH E2D Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Automated Pharmacovigilance Intake Engine',
      'Oracle Argus Safety Electronic Transmission Gateway',
      'Encrypted Multi-Line Medical Information Telephony Suite',
      'Secure Patient Adverse Event Submission Web Portal'
    ],
    regulatoryCompliance: ['UK Good Pharmacovigilance Practice (GPvP)', 'MHRA Yellow Card Scheme Standards', 'ICH E2D Post-Approval Safety Data Management', 'Data Protection Act 2018 / UK GDPR'],
    clinicalSignificance: 'Empowers patients to contribute to real-world safety monitoring, enabling health authorities to update prescribing guidance and protect broader communities.',
    caseStudyOrApplication: {
      heading: 'Detection of Rare Excipient Allergy via Patient Portal',
      synopsis: 'A cluster of 4 mild allergic urticaria reports received via our patient portal following the launch of a new tablet formulation.',
      outcomes: [
        'Medical team identified a specific novel natural coating polymer as the common denominator',
        'Updated patient product information leaflet within 30 days in coordination with the MHRA',
        'Prevented severe allergic reactions in broader patient populations through proactive label transparency'
      ]
    },
    contactFocus: 'Medical Information Helpline & Adverse Event Reporting'
  },
  {
    id: 'our-therapy-areas',
    slug: 'uk-science-our-therapy-areas',
    title: 'Our Therapy Areas: Disease Focus & Clinical Trials',
    category: 'UK Science',
    subCategory: 'Therapy Areas',
    heroBadge: 'Clinical Disease Areas',
    executiveSummary: 'Detailed overview of clinical therapeutic franchises including Immuno-Oncology, Hematology, Autoimmunity, and Rare Metabolic Disorders.',
    leadParagraph: 'Targeting high-burden human diseases with precision biology. We align discovery biology with patient clinical trial cohorts to deliver medicines that change disease outcomes.',
    keyStats: [
      { label: 'Therapy Franchises', value: '4 Core Divisions' },
      { label: 'Clinical Trials Active', value: '14 Studies' },
      { label: 'Trial Participants', value: '4,500+ Patients' },
      { label: 'Collaborating Hospitals', value: '62 Centers' }
    ],
    keyMethodologies: [
      {
        title: 'Precision Immuno-Oncology Targeting',
        description: 'Bispecific T-cell engagers and antibody-drug conjugates engineered to target refractory solid tumors and hematological malignancies.',
        tags: ['Immuno-Oncology', 'Engagers', 'ADCs']
      },
      {
        title: 'Autoimmune B-Cell Silencing',
        description: 'Dual cytokine neutralization therapies targeting BAFF and APRIL pathways to silence auto-reactive B-cell proliferation in Lupus.',
        tags: ['Autoimmunity', 'B-Cells', 'BAFF/APRIL']
      },
      {
        title: 'Genetic Enzyme Replacement via mRNA',
        description: 'Using lipid nanoparticles to deliver modified mRNA encoding therapeutic enzymes for rare genetic lysosomal storage conditions.',
        tags: ['mRNA Therapy', 'Enzyme Replacement', 'Rare Diseases']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Clinical Trial Site Distribution', specification: 'UK, European Union, and North American tertiary centers', standard: 'Global Multi-Center Trials' },
      { parameter: 'Patient Stratification Precision', specification: 'Genomic biomarker panel required for subject enrollment', standard: 'Precision Trial Design' },
      { parameter: 'Data Monitoring Committee (DMC)', specification: 'Independent external safety monitoring for all clinical trials', standard: 'ICH E6(R2) GCP' },
      { parameter: 'Clinical Supply Distribution', specification: 'Dedicated GDP cold-chain delivery within 24 hours of randomization', standard: 'GMP / GDP Guidelines' }
    ],
    instrumentationAndPlatforms: [
      'Clinical Trial Operations Central Command',
      'Electronic Data Capture (EDC) & ePRO Architecture',
      'Central Pharmacokinetic & Biomarker Biobank Vault',
      'Multi-Modality Drug Product Manufacturing Cleanrooms'
    ],
    regulatoryCompliance: ['ICH E6(R2) Good Clinical Practice', 'MHRA Clinical Trial Authorisations', 'FDA Investigational New Drug Approvals', 'Declaration of Helsinki Ethical Principles'],
    clinicalSignificance: 'Ensures that clinical trial investments deliver transformative therapeutic results for patients who have exhausted existing therapies.',
    caseStudyOrApplication: {
      heading: 'Immuno-Oncology Franchise Phase I Dose Escalation',
      synopsis: 'Advancing a first-in-human bispecific mAb in refractory solid tumor patients across 6 UK specialist cancer centres.',
      outcomes: [
        'Successfully completed 5 dose-escalation cohorts without dose-limiting toxicities',
        'Demonstrated target receptor occupancy > 90% at intended therapeutic dose level',
        'Observed confirmed partial responses in heavily pre-treated colorectal cancer patients'
      ]
    },
    contactFocus: 'Clinical Franchise Enquiries & Investigator-Initiated Studies'
  },
  {
    id: 'anti-counterfeit-laboratory',
    slug: 'uk-science-anti-counterfeit-laboratory',
    title: 'Anti-Counterfeit Laboratory & Forensics Facility',
    category: 'UK Science',
    subCategory: 'Analytical & Physical Testing',
    heroBadge: 'Specialist Forensics Lab',
    executiveSummary: 'Dedicated physical laboratory suite specialized in forensic drug testing, packaging authentication, and international law enforcement collaboration.',
    leadParagraph: 'A dedicated facility engineered to protect legitimate supply chains. Our anti-counterfeit laboratory houses advanced spectrometry, microscopic comparison stations, and elemental analyzers dedicated to identifying falsified medical products.',
    keyStats: [
      { label: 'Dedicated Forensics Space', value: '450 m² Secure Lab' },
      { label: 'Spectral Profiles', value: '35,000+ Materials' },
      { label: 'Turnaround Time', value: '24–48 Hours' },
      { label: 'Security Level', value: 'High Containment' }
    ],
    keyMethodologies: [
      {
        title: 'Micro-FTIR Chemical Imaging & Mapping',
        description: 'Mapping chemical distributions across tablet surfaces to identify unauthorized binder excipients and counterfeit blending techniques.',
        tags: ['Micro-FTIR', 'Chemical Mapping', 'Forensics']
      },
      {
        title: 'SEM-EDX Elemental Adulterant Screening',
        description: 'Scanning electron microscopy with energy-dispersive X-ray analysis identifying heavy metal pigments and mineral adulterants.',
        tags: ['SEM-EDX', 'Elemental', 'Adulterants']
      },
      {
        title: 'Forensic Video Spectral Comparator (VSC)',
        description: 'Multi-wavelength optical inspection identifying altered print, counterfeit holographic security foils, and fake batch coding.',
        tags: ['VSC', 'Hologram Inspection', 'Print Analysis']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Forensic Security Containment', specification: 'Tamper-evident vaults with biometric double-custody access', standard: 'Home Office Forensic Rules' },
      { parameter: 'Analytical Mass Resolving Power', specification: '> 70,000 FWHM on Orbitrap HRMS', standard: 'Forensic Mass Spec Standards' },
      { parameter: 'SEM Magnification Range', specification: '20x to 300,000x magnification', standard: 'ISO 22309 Standards' },
      { parameter: 'Evidence Archiving Period', specification: 'Secure physical storage of all case samples for 10 years', standard: 'UK Criminal Justice Act' }
    ],
    instrumentationAndPlatforms: [
      'Foster & Freeman VSC 8000 Comprehensive Forensic Workstation',
      'Thermo Nicolet iN10 MX Infrared Chemical Imaging Microscope',
      'Hitachi SU5000 Variable Pressure Field-Emission SEM with Aztec EDX',
      'Thermo Scientific Orbitrap Exploris 120 Mass Spectrometer'
    ],
    regulatoryCompliance: ['ISO 17025:2017 Forensic Science Accreditation', 'Forensic Science Regulator Code of Practice', 'Home Office Section 5 Firearms and Drug Licences', 'Interpol Anti-Counterfeit Programme Partner'],
    clinicalSignificance: 'Provides decisive physical evidence that enables judicial authorities to shut down counterfeit manufacturing rings, saving patient lives.',
    caseStudyOrApplication: {
      heading: 'Uncovering Multimillion-Pound Counterfeit Cancer Drug Ring',
      synopsis: 'Examining suspect vials of an expensive oncology biologic seized from illegal online distribution channels.',
      outcomes: [
        'VSC optical examination revealed counterfeit security holograms and fake serial numbers',
        'Chemical analysis proved the vials contained only sterile saline with zero active medicine',
        'Delivered court-certified forensic report resulting in international criminal convictions'
      ]
    },
    contactFocus: 'Forensic Authentication Services & Enforcement Collaboration'
  },
  {
    id: 'contributions',
    slug: 'uk-science-contributions',
    title: 'Contributions to Science, Society & Public Health',
    category: 'UK Science',
    subCategory: 'Ecosystem & Strategy',
    heroBadge: 'Social Impact & Science',
    executiveSummary: 'Our impact on British science, published peer-reviewed research, public health initiatives, community education, and environmental sustainability.',
    leadParagraph: 'Science in service of humanity. Beyond commercial drug development, Bedfordshire Biotech actively invests in public health resilience, open academic science, community health screening, and environmental stewardship.',
    keyStats: [
      { label: 'Published Papers', value: '180+ Papers' },
      { label: 'Community Screening', value: '25,000+ Screened' },
      { label: 'Facility Net-Zero', value: '2030 Roadmap' },
      { label: 'Charitable Funding', value: '£2.4M Contributed' }
    ],
    keyMethodologies: [
      {
        title: 'Open Access Scientific Publishing',
        description: 'Publishing core methodological breakthroughs and structural biology findings in open-access journals to accelerate global research.',
        tags: ['Open Access', 'Peer-Review', 'Science Policy']
      },
      {
        title: 'Free Regional Public Health Screenings',
        description: 'Hosting community mobile diagnostic vans offering free blood pressure, diabetes (HbA1c), and cholesterol testing in Greater London.',
        tags: ['Public Health', 'Community Screening', 'Prevention']
      },
      {
        title: 'Green Chemistry & Net-Zero Bioprocessing',
        description: 'Eliminating toxic chlorinated solvents, utilizing 100% renewable electricity, and reclaiming 80% of facility clean water loops.',
        tags: ['Sustainability', 'Green Chemistry', 'Net-Zero 2030']
      }
    ],
    technicalSpecifications: [
      { parameter: 'Open Science Standards', specification: 'FAIR data principles (Findable, Accessible, Interoperable, Reusable)', standard: 'UKRI Open Access Policy' },
      { parameter: 'Carbon Footprint Standard', specification: 'Scope 1, 2, and 3 emissions audited annually under GHG Protocol', standard: 'SBTi Net-Zero Standard' },
      { parameter: 'Renewable Power Share', specification: '100% certified REGO green electricity supply', standard: 'ISO 50001 Energy Management' },
      { parameter: 'Charitable Governance', specification: 'Independent oversight committee directing all philanthropic grants', standard: 'Charity Commission Rules' }
    ],
    instrumentationAndPlatforms: [
      'Enterprise Carbon & Sustainability Telemetry Dashboard',
      'Mobile Community Diagnostic Outreach Clinic Units',
      'Open Science Computational Research Repository',
      'Water Reclamation & Energy Recovery Plant'
    ],
    regulatoryCompliance: ['UN Sustainable Development Goals (SDGs) Aligned', 'NHS Net Zero Supplier Roadmap', 'UKRI Research Concordat', 'ISO 14001:2015 Environmental Management'],
    clinicalSignificance: 'Ensures our scientific success translates directly into public health benefits, cleaner environments, and stronger local communities.',
    caseStudyOrApplication: {
      heading: 'Local NHS Collaboration for Early Cardiovascular Screening',
      synopsis: 'Deploying our mobile healthcare diagnostic units across 12 high-deprivation areas in Bedfordshire and Luton.',
      outcomes: [
        'Screened 6,200 individuals, identifying 480 undiagnosed type 2 diabetes or hypertensive cases',
        'Directly referred identified individuals to local NHS primary care practices for early intervention',
        'Estimated to have prevented dozens of acute cardiovascular events in the local community'
      ]
    },
    contactFocus: 'Public Health Initiatives & ESG Partnership Enquiries'
  }
];

// Helper to look up a UK Science page by slug or id
export function getUkSciencePage(slugOrId: string): SubTopicPageData | undefined {
  return UK_SCIENCE_PAGES.find(p => p.slug === slugOrId || p.id === slugOrId);
}
